() It is planned to spend 6.65 billion yuan to acquire the control right of Huitai Medical, and join forces to cultivate the country’s heavy weapon in the cardiovascular field.
On the evening of January 28th, Mindray Medical, a leading domestic medical device company, announced that it planned to acquire the control right of Huitai Medical, a listed medical device company in science and technology innovation board, by means of "agreement transfer+voting right" with its own funds of 6.65 billion yuan, so as to quickly lay out the subdivision track in cardiovascular field.
According to the acquisition plan, relevant entities such as the actual controller of Huitai Medical intend to transfer 14.12 million shares of Huitai Medical to Shenmai Control, a subsidiary of Mindray Medical, through agreement transfer, accounting for 21.12% of the company’s total share capital. At the same time, Cheng Zhenghui, the controlling shareholder and actual controller of Huitai Medical, will also give up the voting rights of the 10% shares still held.
At the same time as the transfer of this agreement, Shenzhen Maikong intends to acquire all 0.12% general partnership interests of Zhuhai Tongsheng held by Chenyi Hongqi (Mindray Medical holds 99.88% limited partnership interests of Zhuhai Tongsheng), and Zhuhai Tongsheng currently holds 3.49% shares of Huitai. In the end, if all the acquisition plans are successfully implemented, Mindray Medical will hold a total of 24.61% shares of Huitai Medical through its subsidiary Shenmai Control and its concerted action, Zhuhai Tongsheng, and become the largest shareholder of Huitai Medical.
6.65 billion yuan acquisition broke into the cardiovascular super track
For a long time, the field of medical devices has shown the industry characteristics of being strong and persistent. In addition, there are many subdivided tracks and the technology and channel synergy between tracks is limited. After the development of enterprises in the industry enters a certain stage, they all need to rely on extension mergers and acquisitions to cultivate new growth points and continue to expand their business boundaries, which is also true for Mindray Medical, the industry leader.
According to the data of comprehensive industry research report, the global market scale of cardiovascular field has reached 56 billion US dollars, and the market scale of China has also exceeded 50 billion RMB, ranking second in the global and domestic medical device market scale, second only to the field of in vitro diagnosis. In the context of the aging population, the market growth rate in cardiovascular field is significantly higher than that in other fields.
Mindray Medical hopes to quickly cut into the cardiovascular track under the tide of aging population by acquiring the controlling stake of Huitai Medical.
According to public information, as the acquired object, Huitai Medical has been focusing on the cardiovascular track for many years. In the domestic cardiovascular market monopolized by foreign brands, it has achieved a stable position in the segmentation fields such as cardiac electrophysiology, coronary artery access and peripheral vascular intervention, and mastered the full-line R&D and production capacity from upstream raw materials to products. It is a leading enterprise in the domestic cardiovascular field.
Among them, in the field of electrophysiology, the electrophysiology electrode catheter and controllable radiofrequency ablation catheter under Huitai Medical, as well as the floating temporary pacing electrode catheter approved for listing in 2020, are the first domestic products to obtain relevant registration certificates, and are recognized as national key new products by the Ministry of Science and Technology. In the field of vascular intervention, Huitai Medical has been involved in coronary artery access and peripheral vascular intervention, and a number of research and development products have filled the domestic clinical gaps.
Breakthrough innovative products have also brought rapid performance growth to Huitai Medical. In 2023, the company expects to achieve a net profit of 510-565 million yuan, a year-on-year increase of 42%-58%. The company’s value has also been recognized by market investors, and its share price has been stable above 300 yuan/share for a long time, ranking first in science and technology innovation board.
In order to get the leading position in this cardiovascular field, Mindray Medical has also made real money. It is understood that the comprehensive cost of this acquisition is about 450 yuan per share, which is about 25% higher than the latest closing price of Huitai Medical.
In this regard, Mindray Medical explained in the announcement that the starting point and timing of the acquisition of control rights are based on the company’s future strategic development direction and rhythm, aiming to help Mindray Medical quickly cut into the cardiovascular track by acquiring outstanding domestic companies and make positive contributions to Mindray’s long-term rapid growth.
Buying control rights at a premium is also a common operation in the capital market. Referring to the cases of transfer of control rights in Shanghai and Shenzhen Stock Exchanges since 2021, the average premium rate reached 29.58%, among which the average premium rate of medical-related cases reached 32.84%. In addition, in recent years, the average premium rate reached 34.43% in the cases of the transfer of control rights in the field of non-pharmaceutical medical care and health in overseas markets with a transaction scale of more than 500 million US dollars. In addition, from the perspective of Mindray Medical’s cash flow, as of the end of September 2023, the balance of the company’s monetary funds was 19.667 billion yuan, and the transaction amount was less than 1/3 of the book funds, which did not pose great pressure.
Extension acquisition gives birth to a new domestic leader.
In recent years, Mindray Medical has paid special attention to the driving effect of extended mergers and acquisitions on the company’s development. In 2021, the company acquired HyTest Bio, a world-renowned company in the field of IVD raw materials, and realized the independent control of core technologies in the field of IVD raw materials. In 2023, Mindray Medical once again completed the acquisition of DiaSys Holdings in Germany, and successfully built a global supply chain platform for in vitro diagnostic products, laying the foundation for the full internationalization of IVD business.
From the above acquisition cases, it can be found that Mindray Medical always hopes to go deep into the field and intensively cultivate new works with the role of industrial investment integrator, which will bring product R&D innovation and direct improvement of production and sales capabilities for both parties. The acquisition of Huitai Medical will also bring considerable market imagination to the two companies.
In the future, based on the rich experience of Mindray Medical and Huitai Medical in the field of medical equipment and consumables, a brand-new pattern of "Mindray Medical Equipment+Huitai Medical Consumables" is coming out. Mindray’s strong product engineering and system integration capabilities are also expected to further improve the performance of Huitai medical products. Based on Mindray Medical’s in-depth overseas market sales service system and different levels of customer resources, Huitai Medical’s cutting-edge innovative products can also be sold to a broader international market.
It can be said that the combined competitive advantage and cost-effective advantage brought by the combination of strong and powerful forces are becoming the direct weapon for the products of the two companies to break through the global market. The industrial integration with complementary resources is also expected to give birth to a new leader in the industry and open a new export market for domestic medical devices from the cardiovascular track.
Abnormal fluctuation of COFCO Capital’s stock trading, there are no items that should be disclosed but not disclosed.
On January 29th, () disclosed the announcement of abnormal fluctuation of stock trading. The company’s stock trading price has deviated by 30.07% for three consecutive trading days on January 24th, 25th and 26th, which is an abnormal fluctuation of stock trading according to the relevant regulations of Shenzhen Stock Exchange.
The board of directors of the company confirmed that the company has no undisclosed matters or plans, discussions, intentions and agreements related to the matters according to the Listing Rules of Shenzhen Stock Exchange and other relevant provisions; The board of directors has not been informed that the company has information that should be disclosed according to the Listing Rules of Shenzhen Stock Exchange and other relevant regulations, which has a great impact on the trading price of the company’s shares and its derivatives; There is no need to correct or supplement the information disclosed by the company in the early stage.
According to the 2023 annual performance forecast released by COFCO Capital, in 2023, it is estimated that the net profit will be 990 million yuan to 1.06 billion yuan, a year-on-year increase of 65.83% to 77.56%. COFCO Capital said that during the reporting period, in the face of the external environment where opportunities and challenges coexist, the company’s main businesses continued to maintain steady growth, and its investment business effectively resisted market fluctuations. The performance in 2023 is expected to grow in the same direction compared with the same period of last year. (Chloe Wang)
Jianyi Group: Jianxing Construction plans to increase its capital by 40 million yuan to the Second Engineering Company.
On the 27th, () issued an announcement on capital increase to Sun Holding Company.
According to the announcement, at the 40th meeting of the 4th Board of Directors of Jianyi Group, the Proposal on Capital Increase to Holding Sun Company was reviewed and approved. Guangdong Jianxing Construction Group Co., Ltd. (hereinafter referred to as "Jianxing Construction"), a holding subsidiary of the company, plans to increase its capital by 40 million yuan to Guangdong Jianxing Construction Second Engineering Co., Ltd. (hereinafter referred to as "Second Engineering Company") with its own funds. After the capital increase, the registered capital of the second engineering company will be changed from 1,000 yuan.
Regarding this capital increase, Jianyi Group said that Jianxing Construction increased its capital to the Second Engineering Company with its own funds in order to further meet the business development needs of the Second Engineering Company. By increasing its registered capital, it will further enhance its capital strength and enhance its market expansion competitiveness, which will help it participate in the bidding and market expansion of large-scale projects, which is in line with the company’s development strategy.
The main financial indicators of the second engineering company in the latest year and period are as follows:
Huang Weibin, the real controller of Mars, pledged 27.2476 million shares.
() Announcement: Huang Weibin, the controlling shareholder and actual controller of the company, pledged 27,247,600 shares, accounting for 6.67% of the company’s total share capital.
Hyde intends to acquire the controlling stake of Sichuan Haocheng Enterprise Clearing Company to expand bankruptcy management business.
() Announcement. Recently, the company signed the Equity Transfer Agreement with Sichuan Haocheng Enterprise Clearing Company Co., Ltd. (hereinafter referred to as "Clearing Company" or "Target Company") and its shareholders, and the company will acquire 51% equity of the clearing company held by the existing shareholders of the clearing company with its own funds of 17,733,600 yuan. After the completion of this transaction, the liquidation company will become a holding subsidiary within the scope of the company’s consolidated statements.
According to the announcement, the liquidation company is one of the earliest companies specializing in bankruptcy management in China. It has been shortlisted in the roster of administrators of 19 courts and has undertaken hundreds of bankruptcy management cases. The existing staff has rich experience and brand advantages in the industry. After the company obtains the control right of the liquidation company, it will give full play to its resource endowment advantages, gradually expand the bankruptcy management business nationwide, build the liquidation company into a professional liquidation institution with brand influence, and accelerate the transformation of the company into a light asset management model.
Ocean Life appointed Chen Xujun as general manager.
() Announcement: Chen Yanggui, the chairman and general manager of the company, will no longer hold the post of general manager and continue to hold the post of chairman of the company. The board of directors agreed to appoint Chen Xujun as the general manager of the company, with the term of office from the date of deliberation and approval by the board of directors to the expiration of the term of office of the fifth board of directors.
Huali Technology and related personnel received warning letter from Guangdong Securities Regulatory Bureau.
() Announcement. Recently, the company received the Decision on Issuing Warning Letters to Guangzhou Huali Technology Co., Ltd., Su Benli, Hua Shunyang, Feng Zhengchun and Cai Ying issued by Guangdong Securities Regulatory Bureau.
It is reported that the Guangdong Securities Regulatory Bureau conducted an on-site inspection and found that the company had the following problems: 1. The corresponding customers of the company’s individual accounts receivable were cancelled in May 2023, but the company did not find out the change of the customer’s repayment ability in time. It was only in October 2023 that the balance of the accounts receivable was made a single provision for bad debts at 100%, involving an amount of 1,408,300 yuan. The company failed to timely follow up the repayment ability of the debtors of accounts receivable, and failed to timely make provision for bad debts in the semi-annual report of 2023, resulting in untimely and inaccurate disclosure of financial information, which was inconsistent with Article 3, paragraph 1, of the Administrative Measures for Information Disclosure of Listed Companies (Order No.182 of the CSRC, the same below) and Article 48, paragraph 1 of the Accounting Standards for Enterprises No.22-Recognition and Measurement of Financial Instruments (Cai Shui [2017] No.7).
2. The amount of funds raised from equipment investment in the company’s terminal business development project was accounted for by the fair value of the parent company’s book accounting, which did not offset the profit of internal transactions, resulting in inaccurate disclosure data in the special reports on the deposit and use of the company’s raised funds in 2021 and 2022. At the same time, in 2021, the company transferred the raised funds to the non-raised funds account in advance, and used them for investment projects in 2022, involving an amount of 20,235,800 yuan.
3. There are differences between the detailed amount of funds invested by the company in 2021-2022 and the detailed plan for the use of raised funds listed in the prospectus, but the company did not explain the reasons for the differences in time. The above situation does not comply with the first paragraph of Article 3 of the Measures for the Administration of Information Disclosure of Listed Companies, Articles 4 and 11 of Regulatory Guidelines for Listed Companies No.2-Regulatory Requirements for the Management and Use of Funds Raised by Listed Companies (Announcement No.44 of CSRC), and Regulatory Guidelines for Listed Companies No.2-Regulatory Requirements for the Management and Use of Funds Raised by Listed Companies (Announcement of CSRC)
Su Benli is the company’s chairman and general manager, Hua Shunyang is the company’s secretary of the board of directors, Feng Zhengchun is the company’s chief financial officer, and Cai Ying is the company’s then secretary and chief financial officer. Failing to comply with Article 4 of the Measures for the Administration of Information Disclosure of Listed Companies, Article 2 of Regulatory Guidelines for Listed Companies No.2-Regulatory Requirements for the Management and Use of Funds Raised by Listed Companies (Announcement No.44 of CSRC) and Regulatory Guidelines for Listed Companies No.2-Regulatory Requirements for the Management and Use of Funds Raised by Listed Companies (Announcement No.2022 of CSRC)
Hyde shares: it is planned to control the liquidation company to enter the bankruptcy administrator industry.
Hyde announced on the evening of January 29th that recently, the company signed the Equity Transfer Agreement with Sichuan Haocheng Enterprise Clearing Company Limited (hereinafter referred to as "Clearing Company") and its shareholders, and the company will acquire 51% equity of the clearing company held by the existing shareholders of the clearing company with its own funds of 17,733,600 yuan. After the completion of this transaction, the liquidation company will become a holding subsidiary within the scope of the company’s consolidated statements. The liquidation company is the earliest company specializing in bankruptcy management in China and has been shortlisted for the roster of administrators of 19 courts. Through this transaction, the company holds the clearing company and enters the bankruptcy administrator industry.
Two shareholders of Oriental Ocean were informed criticism, and the increase of 110 million yuan was not fulfilled.
On January 29th, 2024, Shenzhen Stock Exchange announced that Hunan Youhe Shenzhou Equity Investment Partnership (Limited Partnership) and Hunan Shenzhou Hanger Capital Management were punished by informed criticism.
Hunan Youhe Shenzhou Equity Investment Partnership (Limited Partnership) and Hunan Shenzhou Hangren Capital Management are shareholders holding more than 5% of Shandong Oriental Ocean Technology. On March 30, 2023, Hunan Youhe Shenzhou Equity Investment Partnership (Limited Partnership) and Hunan Shenzhou Hangzhe Capital Management plan to increase their holdings of Shandong Dongfang Ocean Technology Co., Ltd. within six months, with an increase of not less than 110 million yuan and not more than 220 million yuan, and the average increase price is not higher than 2 yuan/share. However, due to the deterioration of the financial situation of Shandong Oriental Ocean Technology, the continuous increase in the balance of capital occupation, and the failure of the stock price to meet the requirements of the increase plan, Hunan Youhe Shenzhou Equity Investment Partnership (Limited Partnership) and Hunan Shenzhou Hangzhe Capital Management decided to terminate the increase plan. The termination of the shareholding plan was not approved after being reviewed by the shareholders’ meeting of Shandong Oriental Ocean Technology on September 11, 2023. As of the expiration of the holding period, Hunan Shenzhou Hangxing Capital Management has not increased its holding of Shandong Oriental Ocean Technology.
The above behaviors of Hunan Youhe Shenzhou Equity Investment Partnership (Limited Partnership) and Hunan Shenzhou Hanger’s capital management violated Articles 1.4 and 7.7.6 of the Stock Listing Rules (revised in August 2023) of Shenzhen Stock Exchange. According to Article 13.2.3 of the Stock Listing Rules (revised in August, 2023) of Shenzhen Stock Exchange and Article 32 of the Guidelines for Self-regulation of Listed Companies No.12-Implementation Standards for Disciplinary Actions, informed criticism was punished for Hunan Youhe Shenzhou Equity Investment Partnership (Limited Partnership) and Hunan Shenzhou Hanger’s capital management after deliberation and approval by the Disciplinary Committee of Shenzhen Stock Exchange. This violation and punishment will be recorded in the integrity file of listed companies.
Chanz Education: It plans to increase the capital of its subsidiary Datong Haoxue by 260 million yuan.
() Announcement, the company will increase its capital to Datong Haoxue Education Technology Co., Ltd., a wholly-owned subsidiary, with its own capital of 260 million yuan.
Asia Pacific Pharmaceutical: Received the acceptance notice of conformity evaluation of acyclovir for injection.
() Announcement: Recently, the acceptance notice on conformity evaluation of acyclovir for injection was received from National Medical Products Administration.
Chanz Education plans to increase its capital by 260 million yuan to Datong Haoxue, a wholly-owned subsidiary.
Chanz Education announced that in order to meet the capital demand of the company’s fund-raising investment project of issuing convertible corporate bonds to unspecified objects in 2023 and the construction of Datong Internet Vocational and Technical College, and to ensure the smooth implementation of the fund-raising investment project and the normal operation of Datong Internet Vocational and Technical College in the early stage, the company will increase its capital to Datong Haoxue Education Technology Co., Ltd. (hereinafter referred to as "Datong Haoxue") with its own funds of RMB 260 million. After the funds raised in this issuance are in place, all the self-owned funds invested in advance will be replaced by the raised funds in accordance with the procedures stipulated by relevant laws and regulations.
Gudi Technology hired Xu Liang as Chief Financial Officer.
() Announced, nominated by the general manager of the company, reviewed and approved by the Nomination Committee of the fifth board of directors of the company, and reviewed and approved by all members of the Audit Committee of the fifth board of directors. The board of directors agreed to appoint Mr. Xu Liang as the company’s chief financial officer. The term of office of the chief financial officer shall be from the date of deliberation and approval at this meeting to the date of expiration of the term of office of the current board of directors.
On the same day, upon nomination by the chairman of the company, the nomination committee of the fifth board of directors of the company passed the examination, and the board of directors agreed to appoint Ms. Chen Jing as the secretary of the board of directors of the company. The term of office of the secretary of the board of directors shall be from the date of deliberation and approval at this meeting to the date of expiration of the term of office of the current board of directors.
Mr. Xu Xinhua, the former chief financial officer of the company, and Mr. Zhang Dongfeng, the former secretary of the board of directors, ceased to serve as the chief financial officer and secretary of the board of directors of the company respectively due to the expiration of the term of the fourth board of directors of the company.
Asia Pacific Pharmaceutical received the acceptance notice of conformity evaluation of acyclovir for injection.
Asia-Pacific Pharmaceutical announced that the company recently received the acceptance notice of conformity evaluation of acyclovir for injection issued by National Medical Products Administration.
It is reported that acyclovir for injection is suitable for: 1. Herpes simplex virus infection: it is used for the treatment of initial and recurrent mucosal skin infections of immunocompromised people and the prevention of recurrent cases, and also for the treatment of herpes simplex encephalitis; 2. Herpes zoster: used for the treatment of severe herpes zoster in immunocompromised patients or disseminated herpes zoster in immunocompromised patients; 3. Treatment of chickenpox in immunocompromised patients.
According to the announcement, the acceptance of acyclovir for injection in National Medical Products Administration indicates that the conformity evaluation of this variety has entered the review stage, and the company will actively promote the follow-up related work. If the conformity evaluation is successfully passed, its market competitiveness will be enhanced.
Stanley: The net profit in 2023 will increase by 45%-60% year-on-year.
() Announcement, it is estimated that the net profit returned to the mother in 2023 will be 639 million yuan to 705 million yuan, a year-on-year increase of 45%-60%. During the reporting period, the production and sales of the company’s products continued to improve steadily. Thanks to the efficient cooperation of production, supply and marketing, in 2023, the company’s sales volume achieved double-digit growth, and the gross profit space also improved significantly. The increase of sales volume and the promotion of gross profit space have effectively pushed up the company’s profits, making the profits increase greatly year-on-year. In addition, the steady performance of high-margin core product sales has further enhanced the company’s profitability.
Suzhou solid technetium: It is estimated that the net profit in 2023 will have a great impact.
() According to the announcement, it is estimated that in 2023, the impact of non-recurring gains and losses on net profit will be 5 million yuan to 25 million yuan. The total profit reached 148 million yuan, which had a great impact on the company’s net profit. Specific financial data will be disclosed in the company’s 2023 annual report.
Guilin Tourism: It is expected that the 2023 annual report will be published soon.
() The announcement said that the financial data of the company in 2023 will be disclosed in detail in the annual report, and investors are reminded to make careful decisions and pay attention to investment risks. Detailed financial statements will be published in china securities journal, Securities Times and Juchao Information Network. Stay tuned.
Juli Culture: Specific financial data will be disclosed in detail in the company’s 2023 annual financial report.
() According to the announcement, the company’s forecast performance has not been pre-audited by certified public accountants, and the above financial data are the results of preliminary calculations by the company’s financial department. The specific financial data will be disclosed in detail in the company’s 2023 financial report. Investors are advised to invest rationally and pay attention to investment risks. It is hereby announced.
(): Three APIs, namely, levamisole, etoposepa ethanolamine and toremifene citrate, were approved for marketing.
Osekan announced that three APIs, namely, levamisole, etoposepa ethanolamine and toremifene citrate, were approved for marketing.
Watson Pharmaceutical: Obtained the drug registration certificate of rasagiline mesylate tablets.
() Announcement: Recently, the Pharmaceutical Registration Certificate of rasagiline Mesylate Tablets, a product of the company, was approved and issued by National Medical Products Administration.
Production, supply and marketing achieve efficient synergy. Stanley’s net profit in 2023 will increase by 45% to 60% year-on-year.
Stanley announced the announcement of pre-increase of 2023 annual results. The company expects to achieve a net profit of 639 million yuan to 705 million yuan last year, an increase of 45% to 60% over the same period of last year. Realized non-net profit deduction of 568 million yuan to 628 million yuan, an increase of 40% to 55% over the same period of last year; The basic earnings per share is expected to be 0.55 yuan/share to 0.61 yuan/share.
Thanks to the efficient cooperation of production, supply and marketing, the company’s product sales achieved double-digit growth in 2023, and the gross profit space also improved significantly, thus pushing up the company’s profits. In addition, the steady performance of the company’s high-margin core product sales further enhanced the company’s profitability.
In addition, the promotion of new project construction in Songzi during the reporting period led to the year-on-year increase in the expenses of Songzi New Materials Company. With the increase of product sales, some employment expenses of sales companies have also increased significantly; The investment income of joint ventures decreased year-on-year.
In terms of business layout, since 2021, Stanley has invested in the construction of "North-South Phosphorus Chemical Industry" projects in Chengde, Hebei Province and Songzi, Hubei Province respectively. After the above-mentioned projects are completed and put into operation, the two phosphorus chemical production bases in the north and south of the company will echo and cooperate with each other from a distance, and the industrial chain management mode of phosphorus chemical-phosphate fertilizer-compound fertilizer/new energy materials will be built to realize the strategic layout of the company’s phosphorus industrial chain extension. At present, the construction of the above-mentioned projects is progressing steadily, and it is expected to be completed and put into operation one after another this year.
Stanley said that in the future, we will continue to focus on the fertilizer business, continue to consolidate and enhance the existing advantages, expand and extend the upstream phosphorus industrial chain, form the advantages of the industrial chain, continuously improve the company’s comprehensive competitiveness, and lay a solid foundation for the company’s future development.
Mindray Medical intends to be the main enterprise in the field of electrophysiology, Huitai Medical.
Mindray Medical announced on the evening of January 28th that the company intends to acquire 14.12 million ordinary shares of Huitai Medical held by Cheng Zhenghui, Cheng Ling, Dai Zhenhua and other transferors by means of agreement transfer, accounting for 21.12% of the total share capital of the target company, with a total transfer amount of RMB 6.652 billion.
The main business of Huitai Medical is the research and development, production and sales of products such as electrophysiology, coronary artery access and peripheral vascular intervention.
At the same time, Cheng Zhenghui, the actual controller of Huitai Medical, promised to voluntarily, permanently and irrevocably give up the voting rights of 10% of the shares of the target company from the date when he received all the share transfer price according to the agreement.
In addition, Shenmai Control also intends to acquire all 0.12% general partnership interests of Zhuhai Tongsheng Investment Partnership (Limited Partnership) held by Chenyi Hongqi (Beijing) Consulting Co., Ltd. (hereinafter referred to as "Zhuhai Tongsheng"), and Zhuhai Tongsheng currently holds 3.49% shares of Huitai Medical.
After the completion of the above three transactions, Shenmaikong will directly hold 14.12 million shares of Huitai Medical, accounting for 21.12% of the total share capital of Huitai Medical; Zhuhai Tongsheng, the concerted action person of Shenzhen Maikong, directly holds 2,335,300 shares of Huitai Medical, accounting for 3.49% of the total share capital of Huitai Medical. Shenzhen Maikong and its concerted action person Zhuhai Tongsheng hold 16,455,600 shares of Huitai Medical, accounting for 24.61% of the total share capital of Huitai Medical. The controlling shareholder of Huitai Medical will be changed to Shenzhen Maikong, and the actual controllers will be changed to Li Xiting and Xu Hang.
Ropes Jin: The subsidiary plans to set up a wholly-owned subsidiary in Vietnam with no more than US$ 10 million.
On January 29th, () announced that on January 26th, 2024, the company held the 9th meeting of the 6th Board of Directors, and reviewed and approved the Proposal on Foreign Investment of Subsidiaries to Establish Overseas Subsidiaries. In order to open up overseas markets and better provide supporting services for customers, Zhongyifeng Ropes Jinxin Energy Materials Technology (Suzhou) Co., Ltd. plans to set up a wholly-owned subsidiary Zhongyifeng New Energy Materials (Vietnam) Co., Ltd. (tentative name, subject to the registration of Vietnam Industrial and Commercial Registration Authority) in Vietnam with its own funds, mainly engaged in the processing and trade of aluminum alloy photovoltaic frames and aluminum profiles, with a total investment of no more than 10 million US dollars. This foreign investment is within the approval authority of the board of directors of the company and does not need to be submitted to the shareholders’ meeting of the company for deliberation.
Zhonghe Technology plans to further acquire 35.46% equity of Guoke Zhonghe to optimize the investment asset structure.
() Announced that Guoke Zhonghe Innovation Group Co., Ltd. ("Guoke Zhonghe") is a holding subsidiary of the company. It is an innovative investment platform jointly established by Zhonghe Technology, Zhejiang Bozhong Shuzhi Technology Innovation Group Co., Ltd. ("Bozhong Shuzhi") and Western Advantage (Baoji) Industrial Equity Investment Fund (Limited Partnership) ("Western Fund"), which follows the principle of "two controls and many participants".
In order to give full play to the value of Guoke Zhonghe investment management platform, improve its investment asset management efficiency and optimize its investment asset structure, the company plans to acquire the equity of Guoke Zhonghe held by related party Bozhong Shuzhi, and further improve the company’s control over high-tech industrial chains and industry ecology such as integrated circuits and industrial Internet.
In this transaction, the company intends to acquire 35.46% equity of Guoke Zhonghe (corresponding to the registered capital of 35.7265 million yuan) held by related party Bozhong Digital Intelligence, and the transfer price is 98.6387 million yuan. After the completion of this transaction, the company holds a total of 95.02% equity of Guoke Zhonghe.
Hualan vaccine and its responsible person are warned if the cash management amount exceeds the authorized amount.
On the evening of January 26th, () announced that the company had recently received the "Decision on Taking Measures to Issue Warning Letters to () Vaccine Co., Ltd. and Relevant Responsible Persons" issued by Henan Supervision Bureau of China Securities Regulatory Commission (hereinafter referred to as "Warning Letter").
According to the Warning Letter, from April 8 to June 7, June 16 to 29, and July 5 to 11, 2022, the amount of cash management raised by Hualan Vaccine exceeded the amount authorized by the board of directors. During this period, the maximum amount of cash management of the company was 1.25 billion yuan, which exceeded the amount reviewed by the board of directors by 250 million yuan and was not disclosed in time.
The Henan Securities Regulatory Bureau determined that the above matters violated the provisions of Article 3, paragraph 1, of the Measures for the Administration of Information Disclosure of Listed Companies (Order No.182 of the CSRC) and Article 8, paragraph 2 of the Regulatory Guidelines for Listed Companies No.2-Regulatory Requirements for the Management and Use of Funds Raised by Listed Companies (Announcement No.15 of the CSRC [2022]). Lv Chengyu, secretary of the board of directors and chief financial officer of the company, is mainly responsible for the above violations. According to the provisions of Article 52 of the Measures for the Administration of Information Disclosure of Listed Companies, Henan Securities Regulatory Bureau decided to take administrative supervision measures to issue warning letters to Hualan Vaccine and Lv Chengyu, and record them in the integrity files of the securities and futures markets.
According to public information, the main business of Hualan vaccine is research and development, production and sales of human vaccines.
On the evening of January 23, 2024, the performance forecast disclosed by Hualan Vaccine showed that the company expected to achieve a net profit of about 750-950 million yuan in 2023, a year-on-year increase of 44%-82%. For the reasons of performance growth, Hualan Vaccine said that the demand for influenza vaccine market was strong in 2023, and the company’s influenza vaccine sales increased significantly compared with the previous year, so the net profit in 2023 increased in the same direction as that in the previous year; The company expects that the impact of non-recurring gains and losses in 2023 on the current net profit will be about 100 million yuan, compared with 67.95 million yuan in the same period last year.
Osekan: Three APIs, such as dextrolansoprazole, were approved for marketing.
Osekan announced that Nanjing Hairun Pharmaceutical Co., Ltd. (hereinafter referred to as the "subsidiary"), a wholly-owned subsidiary of the company, recently received the Notice of Approval for the Listing Application of Three APIs, namely, levamisole, escitalopram and toremifene citrate, issued by National Medical Products Administration. The approval of the listing of the three APIs will enhance the competitiveness of the company’s integration of characteristic APIs and preparations, and enhance the company’s cost advantage and comprehensive operational efficiency.
Star Shuaier: Obtained a trademark registration certificate.
On the evening of January 29th, () announced that the company had recently obtained a trademark registration certificate issued by China National Intellectual Property Administration. Approved use of goods or services for solar water heaters or solar collectors.
Ocean Life: Chen Xujun was appointed as the general manager of the company.
On the evening of January 29th, Ocean Bio announced that the company held the 15th meeting of the fifth board of directors on January 26th, 2024, and unanimously reviewed and approved the Proposal on Changing the General Manager. In order to ensure the smooth development of the company’s operation and management, the nomination committee of the board of directors approved the nomination of Mr. Chen Yanggui, the chairman of the board of directors, and agreed to appoint Ms. Chen Xujun as the general manager of the company, with the term from the date of review and approval by the board of directors to the expiration of the term of the fifth board of directors.
Gudi Technology: Xu Liang was appointed as the Chief Financial Officer and Chen Jing as the Secretary-General.
On the evening of January 29th, Gudi Technology announced that on January 29th, 2024, the company held the fifth meeting of the fifth board of directors, and deliberated and passed the Proposal on Appointing Senior Managers of the Company, which was nominated by the general manager of the company, reviewed and passed by the Nomination Committee of the fifth board of directors, and passed by all members of the Audit Committee of the fifth board of directors. The board of directors agreed to appoint Mr. Xu Liang as the company’s chief financial officer, and the term of the chief financial officer will expire from the date of deliberation and approval of this meeting. On the same day, upon nomination by the chairman of the company, the nomination committee of the fifth board of directors of the company passed the examination, and the board of directors agreed to appoint Ms. Chen Jing as the secretary of the board of directors of the company. The term of office of the secretary of the board of directors shall be from the date of deliberation and approval at this meeting to the date of expiration of the term of office of the current board of directors.
Shaanxi Huada: The company was recognized as a high-tech enterprise again.
On the evening of January 29th, () announced that the company had recently received the High-tech Enterprise Certificate jointly issued by Shaanxi Provincial Department of Science and Technology, Shaanxi Provincial Department of Finance and Shaanxi Provincial Taxation Bureau of State Taxation Administration of The People’s Republic of China. Within three consecutive years (from 2023 to 2025) after the company obtained the new certificate of high-tech enterprise, it will enjoy the relevant preferential tax policies of the state on high-tech enterprises, that is, pay enterprise income tax at the rate of 15%.
Mingke Jingji: The company and its subsidiaries are re-recognized through high-tech enterprises.
On the evening of January 29th, () announced that the company and its subsidiary Guangdong Zengtian Sheng ‘an Automobile Parts Manufacturing Co., Ltd. (hereinafter referred to as "Guangdong Zengtian") recently received the high-tech enterprise certificate jointly issued by Guangdong Provincial Department of Science and Technology, Guangdong Provincial Department of Finance and State Taxation Administration of The People’s Republic of China Guangdong Provincial Taxation Bureau, and this recognition was re-recognized after the expiration of the certificate of the company and its subsidiary Guangdong Zengtian original high-tech enterprise.
Asia Pacific Pharmaceuticals: Received the acceptance notice on conformity evaluation of acyclovir for injection.
On the evening of January 29th, Asia Pacific Pharmaceuticals announced that it had recently received the acceptance notice of conformity evaluation of acyclovir for injection from National Medical Products Administration. Acyclovir for injection is suitable for: 1. Herpes simplex virus infection: it is used for the treatment of primary and recurrent mucosal skin infections of immunocompromised people, the prevention of recurrent cases, and also for the treatment of herpes simplex encephalitis; 2. Herpes zoster: used for the treatment of severe herpes zoster in immunocompromised patients or disseminated herpes zoster in immunocompromised patients; 3. Treatment of chickenpox in immunocompromised patients.
Taixiang Co., Ltd. will hold a general meeting of shareholders on February 26, and three proposals will be considered.
() Announce that the first extraordinary general meeting of shareholders will be held on February 26th, 2024, and online voting will be conducted on the same day. Date of record is February 19th, and investors who hold shares of Taixiang can vote after the market closes on that day.
Meeting place: Company meeting room, No.258 Jilin Road, Shiyan Economic and Technological Development Zone, Hubei Province.
A total of three proposals were audited at this general meeting of shareholders, as follows:
1. Proposal on Using Part of Idle Raised Funds for Cash Management
2. Proposal on Using Idle Own Funds for Cash Management
3. Proposal on Providing Financial Support to Holding Subsidiaries.
Yiming Medicine: It is estimated that the goodwill will be impaired by about 18 million to 21 million yuan during the reporting period.
() It was announced that the operating performance of Inner Mongolia Bostai Enterprise Management Service Co., Ltd., a holding subsidiary of the company, failed to meet expectations. In order to reflect the company’s financial position and asset value more objectively and fairly, the company and Bostai management team conducted a goodwill impairment test at the end of the reporting period in accordance with the principle of prudence, the Accounting Standards for Business Enterprises No.8-Asset Impairment and other relevant accounting policies, combined with factors such as industry development, market changes and Bostai’s actual operation, and it is estimated that the amount of goodwill impairment will be withdrawn. The relevant impairment test is still in progress, and the final amount of impairment reserve for goodwill will be determined after evaluation and audit by qualified evaluation institutions and audit institutions hired by the company.
(): Signed the Cooperation Framework Agreement with PetroChina in South China.
Langkun Environment announced on the evening of January 29th that the company recently signed the Cooperation Framework Agreement with South China Petrochina International Co., Ltd. (hereinafter referred to as "South China Petrochina"), and the two parties will strengthen future business cooperation on SAF (sustainable aviation fuel) products; Strengthen the follow-up business cooperation on UCO (industrial mixed oil) products; Strengthen cooperation in biological ship fuel business, etc.
Sui Hengyun A: participated in the establishment of a company to build a polypropylene plant project.
Sui Hengyun announced on the evening of January 29th that the company participated in the establishment of Guangzhou Mingzhu High-end New Materials Co., Ltd. and invested in the construction of a 350,000-ton/year polypropylene plant joint venture project (hereinafter referred to as "polypropylene plant project"). The total investment of the project for approval is 1.266 billion yuan, and the project capital accounts for 30% of the total investment for approval, that is, the registered capital of Guangzhou Mingzhu High-end New Materials Co., Ltd. is 380 million yuan, of which, the Company contributes 38 million yuan in cash and holds 10% of its equity.
Watson Pharmaceutical: rasagiline Mesylate Tablets obtained the drug registration certificate.
Huasen Pharmaceutical announced that the company recently received the Pharmaceutical Registration Certificate for its product, rasagiline Mesylate Tablets, approved and issued by National Medical Products Administration ("National Medical Products Administration").
According to the data of Yaozhi. com, the overall market share of rasagiline mesylate tablets will be 121 million yuan in 2022. This drug is suitable for the single treatment of patients with primary Parkinson’s disease (PD) (without levodopa) and for Parkinson’s patients with terminal fluctuation as an auxiliary drug of levodopa. It is recommended by Guidelines for the Treatment of Parkinson’s Disease in China, Guidelines for the Diagnosis and Treatment of Mild Cognitive Impairment of Parkinson’s Disease in China (2020 Edition) and Guidelines for Evidence-based Medicine for the Treatment of Motor Symptoms of Parkinson’s Disease in China.
According to the announcement, rasagiline mesylate tablets won the Pharmaceutical Registration Certificate, which will help to further enrich the company’s product line, enhance the company’s market competitiveness, and benefit more patients. At the same time, it will also help to form a market synergy with the company’s existing Duliang soft capsules, Liuwei Anshen capsules and other products in the field of mental nervous system, create a product cluster in advantageous fields, and have a positive impact on the company’s production and operation.
() A general meeting of shareholders will be held on February 21st to consider the proposal of increasing registered capital and amending the Articles of Association.
Runhe Materials announced that the first extraordinary general meeting of shareholders will be held on February 21, 2024, and online voting will be held on the same day. Date of record falls on February 8th, and investors who hold shares of Runhe Materials can vote after the market closes on that day.
Meeting place: meeting room of Ningbo Runhe High-tech Materials Technology Co., Ltd. (No.168 Jinhai Middle Road, South Binhai New Area, Ninghai County, Ningbo, Zhejiang Province).
A total of 1 proposal was audited at this general meeting of shareholders, as follows:
1. Proposal on increasing registered capital and amending the Articles of Association.
Hyde shares: it is planned to hold a clearing company and enter the bankruptcy administrator industry.
On January 29th, Hyde announced that recently, the company signed the Equity Transfer Agreement with Sichuan Haocheng Enterprise Clearing Company Limited (hereinafter referred to as "Clearing Company") and its shareholders, and the company will acquire 51% equity of the clearing company held by the existing shareholders of the clearing company with its own funds of 17,733,600 yuan. After the transaction is completed, the liquidation company will become a holding subsidiary within the scope of the company’s consolidated statements.
It is reported that the liquidation company is one of the earliest companies specializing in bankruptcy management in China, and has been shortlisted for the roster of administrators of 19 courts. Through this transaction, the company holds the clearing company and enters the bankruptcy administrator industry.
The letter is not timely and accurate. Huali Technology received a warning letter.
Huali Technology announced on the evening of January 29th that the Guangdong Securities Regulatory Bureau has recently taken administrative supervision measures to issue warning letters to the company and relevant responsible persons. Previously, when the Guangdong Securities Regulatory Bureau conducted an on-site inspection of Huali Technology, it found that the company had problems in the provision for bad debts of accounts receivable, the management and use of funds raised by the company.
According to the announcement of Huali Science and Technology, Guangdong Securities Regulatory Bureau found that the corresponding customers of the company’s individual accounts receivable had been cancelled in May 2023, but the company did not find the change of customers’ repayment ability in time, and only in October 2023 did it make a single provision for bad debts in the third quarter report based on 100% of the accounts receivable balance, involving an amount of 1,408,300 yuan. The company failed to follow up the repayment ability of the debtor of accounts receivable in time, and failed to make provision for bad debts in time in the semi-annual report of 2023, resulting in untimely and inaccurate disclosure of financial information and non-compliance with relevant regulations.
In addition, the amount of funds raised by the equipment investment in the terminal business development project of Huali Technology was recorded by the fair value of the parent company’s book accounting, which did not offset the profit of internal transactions, resulting in inaccurate disclosure data in the special report on the deposit and use of funds raised by the company in 2021 and 2022. At the same time, in 2021, the company transferred the raised funds to the non-raised funds account in advance, and used them for investment projects in 2022, involving an amount of 20,235,800 yuan.
The inspection by Guangdong Securities Regulatory Bureau also found that there was a difference between the detailed amount of funds invested by Huali Technology during 2021-2022 and the detailed plan for the use of raised funds listed in the prospectus, but the company did not explain the reasons for the difference in time. The above situation does not comply with relevant regulations.
According to Article 52 of the Measures for the Administration of Information Disclosure of Listed Companies, Guangdong Securities Regulatory Bureau decided to take administrative supervision measures of issuing warning letters to companies and related responsible persons.
Huali Technology said that the company will deeply reflect on the problems and shortcomings in financial management and fund-raising management, and will carry out rectification in strict accordance with the requirements of Guangdong Securities Regulatory Bureau.
Huali Technology is a leading enterprise of integrated service providers for the distribution and operation of commercial game amusement equipment in China, covering the design, research and development, production, sales and operation of game amusement equipment, forming a complete industrial chain.
Huali Technology disclosed its 2023 annual performance forecast on January 27, and the company expects to realize a net profit of 50 million yuan to 60 million yuan, with a loss of 71.2155 million yuan in the same period last year.
Regarding the reasons for the change in performance, Huali Technology said that the macro-environmental impact in the early stage was gradually eliminated, the residents’ life and cultural and entertainment consumption returned to normal, the domestic indoor entertainment format was operating normally, and the company’s operating conditions improved significantly compared with the same period of last year. During the reporting period, offline experiential consumption recovered quickly, the willingness of downstream amusement park customers to invest in new stores increased significantly, and the sales of game and entertainment equipment of the company continued to grow. At the same time, with the steady expansion of the number and coverage of the company’s animation and cartoon equipment, the sales revenue of the company’s animation IP derivative products has greatly increased.
In addition, the company strengthens product promotion, cooperates with () marketing, continuously penetrates users of different ages, develops new users’ cognition and cultivates users’ stickiness; At the same time, adhere to differentiated innovation, promote product renewal iteration, and ensure steady growth of sales through multi-pronged, and the company’s profitability continues to improve.
Beiwei Technology: Repurchase 182,400 shares for the first time.
On the evening of January 29th, () announced that on January 29th, 2024, the company repurchased 182,400 shares of the company for the first time through the special securities account for stock repurchase, accounting for 0.03% of the company’s total share capital. The highest transaction price was 5.30 yuan/share, the lowest transaction price was 5.22 yuan/share, and the total transaction amount was 958,815.00 yuan (excluding transaction fees).
Chanz Education plans to increase its capital by 260 million yuan to its subsidiary Datong Haoxue.
On January 29th, Chanz Education announced that in order to meet the capital demand of the company’s investment project of issuing convertible corporate bonds to unspecified objects in 2023 and the construction of Datong Internet Vocational and Technical College, and to ensure the smooth implementation of the investment project of raised funds and the normal operation of Datong Internet Vocational and Technical College in the early stage, the company will increase its capital to its wholly-owned subsidiary Datong Haoxue Education Technology Co., Ltd. (hereinafter referred to as "Datong Haoxue") with its own funds of 260 million yuan.
The announcement shows that after the completion of this capital increase, the registered capital of Datong Haoxue has increased from 300 million yuan to 560 million yuan, and it is still a wholly-owned subsidiary of the company. After the funds raised in this issuance are in place, Chanz Education will replace all its own funds invested in advance with the raised funds in accordance with the procedures stipulated by relevant laws and regulations.
Minde Electronics: It is planned to buy back shares at a price of 15 million to 30 million yuan.
() On the evening of January 29th, it was announced that the company planned to buy back shares at a price of 15 million yuan to 30 million yuan, all of which would be cancelled and the registered capital would be reduced. The price of the shares to be bought back should not exceed 34.11 yuan per share. The company released a performance forecast on the same day, and it is estimated that the net profit of returning to the mother in 2023 will be 21 million to 27 million yuan, down 69.9% to 76.59% year-on-year.
Zhang Xiaoquan: It is planned to buy back the shares of the company from 30 million yuan to 40 million yuan.
On January 29th, () announced that it planned to buy back the company’s shares from 30 million yuan to 40 million yuan, and the price limit for this share repurchase was 206.6 yuan/share.
Ligao Food: It is planned to buy back shares at a price of 50 million yuan to 100 million yuan.
() It was announced on the evening of January 29th that the company plans to buy back shares at a price of RMB 50 million to RMB 100 million for the implementation of equity incentive or employee stock ownership plan, and the repurchase price is no more than RMB 66.6 per share. The company issued a performance forecast on the same day, and it is estimated that the net profit of returning to the mother in 2023 will be 80 million yuan to 105 million yuan, a year-on-year decrease of 26.97% to 44.36%.
Minde Electronics will hold a shareholders’ meeting on February 19th to consider the proposal of repurchasing the company’s shares.
Minde Electronics announced that the second extraordinary shareholders’ meeting will be held on February 19, 2024, and online voting will be conducted on the same day. Date of record is February 5th, and investors who hold shares of Minde Electronics can vote after the market closes on that day.
Meeting place: 5th floor, Section 1, Building 25, Industrial Workshop, Central Science Park, High-tech Zone, Nanshan District, Shenzhen, China.
A total of 1 proposal was audited at this general meeting of shareholders, as follows:
1. Proposal on the Plan of Repurchase of Shares of the Company.
Gaole Co., Ltd.: The subsidiary signed a cooperation agreement on technology research and development.
() On the evening of January 29th, it was announced that the company’s wholly-owned subsidiary, Gaole New Energy Technology (Zhejiang) Co., Ltd. (hereinafter referred to as "Gaole New Energy") and Chongqing Nikolai Science and Technology Industry Research Institute Co., Ltd. (hereinafter referred to as "Nikolai Research Institute") signed the Technical Research and Development Cooperation Agreement for the Development and Research Project of Nanometer Solid Sodium Ion Battery, which was entrusted by Gaole New Energy to Nikolai Research Institute for research and development, and accepted by Nikolai Research Institute.
Tang Changmao, chairman and general manager of Yibo Technology, proposed to spend 30 million yuan to 60 million yuan to implement repurchase.
() Announcement, Tang Changmao, the chairman and general manager of the company, proposed that the company buy back some A shares issued by the company through centralized bidding transaction with its own funds, and buy back shares at an appropriate time for implementing employee stock ownership plan or equity incentive. The upper limit of the price of repurchased shares is not higher than 150% of the average trading price of the company’s shares in the 30 trading days before the board of directors deliberated and passed the resolution on the repurchase plan. The total amount of funds for this share repurchase is not less than 30 million yuan and not more than 60 million yuan; The implementation period of repurchase is within 12 months from the date when the company’s board of directors deliberated and approved the repurchase plan.
Western Securities: 1.5 billion short-term financing bonds were issued, with coupon rate accounting for 2.45%.
() It was announced this evening that the first phase of short-term financing bonds of the company in 2024 (referred to as "24 Western Securities CP001", code 072410018) was issued on January 26, 2024, with the payment date of January 29, 2024. The actual issuance amount was RMB 1.5 billion, with coupon rate accounting for 2.45%, the term was 85 days, and the value was January 2024.
The domestic consumer market has been steadily restored, and the performance of many textile and garment listed companies has been pre-happy.
In the context of the recovery of the terminal consumption environment, (), () and other textile and garment listed companies issued pre-increase announcements.
Senma Clothing released its annual performance forecast for 2023 on the evening of January 29th. The company expects to achieve a net profit of 1.06 billion yuan to 1.16 billion yuan in 2023, up 66.41% to 82.1% year-on-year. The non-net profit deducted was 970 million yuan to 1.07 billion yuan, a year-on-year increase of 95.04% to 115.15%.
Regarding the reasons for the change in performance, Senma Apparel said that during the reporting period, the company continued to promote organizational change, model innovation and process reengineering, strengthened the organizational capacity of retail business, comprehensively promoted the implementation of new retail models, and realized the mutual empowerment of online and offline, direct sales and franchise businesses. The company’s operational quality and efficiency improved, the sales gross profit margin increased year-on-year, and the gross profit increased year-on-year; The company’s inventory operation efficiency increased year-on-year, inventory turnover days decreased year-on-year, ending inventory balance decreased year-on-year, and asset impairment losses decreased year-on-year.
On the evening of January 29th, Seven Wolves simultaneously disclosed the annual performance forecast for 2023. It is estimated that the net profit in 2023 will reach 241 million yuan to 301 million yuan, up 60% to 100% year-on-year. The non-net profit deducted was 169 million yuan to 211 million yuan, up 60% to 100% year-on-year.
Seven wolves said that during the reporting period, the terminal consumption environment recovered, the company’s operating income increased, terminal discounts were effectively controlled, and the gross profit margin of products increased, so the total profit increased compared with the same period of last year.
Prior to this, () the annual performance forecast for 2023 was released on January 26th, and it is estimated that the net profit in 2023 will reach 688 million yuan to 734 million yuan, a year-on-year increase of 50% to 60%. The non-net profit was deducted from 586 million yuan to 632 million yuan, a year-on-year increase of 56.57%-68.82%.
As for the reasons for the change in performance, Baoxiniao said that during the reporting period, the company actively promoted the implementation of the business plans of various brands, and continuously improved the product strength, channel strength, brand strength and operational strength. All the brands under Baoxiniao, Haggis, Baodiao, Lefeiye and Camiche achieved growth compared with the same period of last year, and the main business income achieved good growth. During the reporting period, the company continued to innovate and upgrade products, improve product quality, strictly control terminal discounts, and achieved rapid growth in direct sales channels and increased gross profit margin.
The above-mentioned companies expect their performance to achieve year-on-year growth in 2023, which is inseparable from the background of the recovery of the domestic consumer market.
After three years of epidemic, with a series of policies to promote consumption continuing to exert significant effects, the domestic consumer market will maintain a stable recovery in 2023.
According to statistics disclosed by the National Bureau of Statistics on January 17th, the total retail sales of social consumer goods in 2023 was 47,149.5 billion yuan, an increase of 7.2% over the previous year. By consumption type, the retail sales of commodities was 41,860.5 billion yuan, an increase of 5.8%; The catering revenue was 5,289 billion yuan, an increase of 20.4%. The sales of basic daily necessities increased steadily. The retail sales of clothing, shoes and hats, knitwear, grain, oil and food commodities above designated size increased by 12.9% and 5.2% respectively.
In 2023, the per capita consumption expenditure of the national residents was 26,796 yuan, a nominal increase of 9.2% over the previous year, and a real increase of 9.0% after deducting the price factor. The per capita clothing consumption expenditure was 1,479 yuan, up by 8.4%, accounting for 5.5% of the per capita consumption expenditure.
Senma Clothing had previously said in an institutional survey that the market sales were recovering, basic life and upgraded goods were selling well, online consumption grew rapidly, and service consumption demand continued to be released. Offline passenger traffic has gradually picked up, and new consumption scenes such as characteristic commercial blocks and brand experience stores have emerged, which has driven the continuous improvement of physical store operations.
In the latest research report, soochow securities believes that the textile and apparel industry will make brilliant achievements in 2023 thanks to the post-epidemic restoration. In 2024, the growth rate of overall clothing consumption slowed down compared with that in 2023 due to the improvement of the base and the overall consumption environment, but the structural repair continued, and new trends brought new opportunities.
The domestic consumer market has been steadily restored, and the performance of many textile and garment listed companies has been pre-happy.
In the context of the recovery of the terminal consumption environment, listed textile and garment companies such as Senma Apparel and Seven Wolves have issued pre-increased performance announcements.
Senma Clothing released its annual performance forecast for 2023 on the evening of January 29th. The company expects to achieve a net profit of 1.06 billion yuan to 1.16 billion yuan in 2023, up 66.41% to 82.1% year-on-year. The non-net profit deducted was 970 million yuan to 1.07 billion yuan, a year-on-year increase of 95.04% to 115.15%.
Regarding the reasons for the change in performance, Senma Apparel said that during the reporting period, the company continued to promote organizational change, model innovation and process reengineering, strengthened the organizational capacity of retail business, comprehensively promoted the implementation of new retail models, and realized the mutual empowerment of online and offline, direct sales and franchise businesses. The company’s operational quality and efficiency improved, the sales gross profit margin increased year-on-year, and the gross profit increased year-on-year; The company’s inventory operation efficiency increased year-on-year, inventory turnover days decreased year-on-year, ending inventory balance decreased year-on-year, and asset impairment losses decreased year-on-year.
On the evening of January 29th, Seven Wolves simultaneously disclosed the annual performance forecast for 2023. It is estimated that the net profit in 2023 will reach 241 million yuan to 301 million yuan, up 60% to 100% year-on-year. The non-net profit deducted was 169 million yuan to 211 million yuan, up 60% to 100% year-on-year.
Seven wolves said that during the reporting period, the terminal consumption environment recovered, the company’s operating income increased, terminal discounts were effectively controlled, and the gross profit margin of products increased, so the total profit increased compared with the same period of last year.
Prior to this, the good news bird released its annual performance forecast for 2023 on January 26, and it is estimated that the net profit will reach 688 million yuan to 734 million yuan in 2023, up 50% to 60% year-on-year. The non-net profit was deducted from 586 million yuan to 632 million yuan, a year-on-year increase of 56.57%-68.82%.
As for the reasons for the change in performance, Baoxiniao said that during the reporting period, the company actively promoted the implementation of the business plans of various brands, and continuously improved the product strength, channel strength, brand strength and operational strength. All the brands under Baoxiniao, Haggis, Baodiao, Lefeiye and Camiche achieved growth compared with the same period of last year, and the main business income achieved good growth. During the reporting period, the company continued to innovate and upgrade products, improve product quality, strictly control terminal discounts, and achieved rapid growth in direct sales channels and increased gross profit margin.
The above-mentioned companies expect their performance to achieve year-on-year growth in 2023, which is inseparable from the background of the recovery of the domestic consumer market.
After three years of epidemic, with a series of policies to promote consumption continuing to exert significant effects, the domestic consumer market will maintain a stable recovery in 2023.
According to statistics disclosed by the National Bureau of Statistics on January 17th, the total retail sales of social consumer goods in 2023 was 47,149.5 billion yuan, an increase of 7.2% over the previous year. By consumption type, the retail sales of commodities was 41,860.5 billion yuan, an increase of 5.8%; The catering revenue was 5,289 billion yuan, an increase of 20.4%. The sales of basic daily necessities increased steadily. The retail sales of clothing, shoes and hats, knitwear, grain, oil and food commodities above designated size increased by 12.9% and 5.2% respectively.
In 2023, the per capita consumption expenditure of the national residents was 26,796 yuan, a nominal increase of 9.2% over the previous year, and a real increase of 9.0% after deducting the price factor. The per capita clothing consumption expenditure was 1,479 yuan, up by 8.4%, accounting for 5.5% of the per capita consumption expenditure.
Senma Clothing had previously said in an institutional survey that the market sales were recovering, basic life and upgraded goods were selling well, online consumption grew rapidly, and service consumption demand continued to be released. Offline passenger traffic has gradually picked up, and new consumption scenes such as characteristic commercial blocks and brand experience stores have emerged, which has driven the continuous improvement of physical store operations.
In the latest research report, soochow securities believes that the textile and apparel industry will make brilliant achievements in 2023 thanks to the post-epidemic restoration. In 2024, the growth rate of overall clothing consumption slowed down compared with that in 2023 due to the improvement of the base and the overall consumption environment, but the structural repair continued, and new trends brought new opportunities.
The domestic consumer market has been steadily restored, and the performance of many textile and garment listed companies has been pre-happy.
In the context of the recovery of the terminal consumption environment, listed textile and garment companies such as Senma Apparel and Seven Wolves have issued pre-increased performance announcements.
Senma Clothing released its annual performance forecast for 2023 on the evening of January 29th. The company expects to achieve a net profit of 1.06 billion yuan to 1.16 billion yuan in 2023, up 66.41% to 82.1% year-on-year. The non-net profit deducted was 970 million yuan to 1.07 billion yuan, a year-on-year increase of 95.04% to 115.15%.
Regarding the reasons for the change in performance, Senma Apparel said that during the reporting period, the company continued to promote organizational change, model innovation and process reengineering, strengthened the organizational capacity of retail business, comprehensively promoted the implementation of new retail models, and realized the mutual empowerment of online and offline, direct sales and franchise businesses. The company’s operational quality and efficiency improved, the sales gross profit margin increased year-on-year, and the gross profit increased year-on-year; The company’s inventory operation efficiency increased year-on-year, inventory turnover days decreased year-on-year, ending inventory balance decreased year-on-year, and asset impairment losses decreased year-on-year.
On the evening of January 29th, Seven Wolves simultaneously disclosed the annual performance forecast for 2023. It is estimated that the net profit in 2023 will reach 241 million yuan to 301 million yuan, up 60% to 100% year-on-year. The non-net profit deducted was 169 million yuan to 211 million yuan, up 60% to 100% year-on-year.
Seven wolves said that during the reporting period, the terminal consumption environment recovered, the company’s operating income increased, terminal discounts were effectively controlled, and the gross profit margin of products increased, so the total profit increased compared with the same period of last year.
Prior to this, the good news bird released its annual performance forecast for 2023 on January 26, and it is estimated that the net profit will reach 688 million yuan to 734 million yuan in 2023, up 50% to 60% year-on-year. The non-net profit was deducted from 586 million yuan to 632 million yuan, a year-on-year increase of 56.57%-68.82%.
As for the reasons for the change in performance, Baoxiniao said that during the reporting period, the company actively promoted the implementation of the business plans of various brands, and continuously improved the product strength, channel strength, brand strength and operational strength. All the brands under Baoxiniao, Haggis, Baodiao, Lefeiye and Camiche achieved growth compared with the same period of last year, and the main business income achieved good growth. During the reporting period, the company continued to innovate and upgrade products, improve product quality, strictly control terminal discounts, and achieved rapid growth in direct sales channels and increased gross profit margin.
The above-mentioned companies expect their performance to achieve year-on-year growth in 2023, which is inseparable from the background of the recovery of the domestic consumer market.
After three years of epidemic, with a series of policies to promote consumption continuing to exert significant effects, the domestic consumer market will maintain a stable recovery in 2023.
According to statistics disclosed by the National Bureau of Statistics on January 17th, the total retail sales of social consumer goods in 2023 was 47,149.5 billion yuan, an increase of 7.2% over the previous year. By consumption type, the retail sales of commodities was 41,860.5 billion yuan, an increase of 5.8%; The catering revenue was 5,289 billion yuan, an increase of 20.4%. The sales of basic daily necessities increased steadily. The retail sales of clothing, shoes and hats, knitwear, grain, oil and food commodities above designated size increased by 12.9% and 5.2% respectively.
In 2023, the per capita consumption expenditure of the national residents was 26,796 yuan, a nominal increase of 9.2% over the previous year, and a real increase of 9.0% after deducting the price factor. The per capita clothing consumption expenditure was 1,479 yuan, up by 8.4%, accounting for 5.5% of the per capita consumption expenditure.
Senma Clothing had previously said in an institutional survey that the market sales were recovering, basic life and upgraded goods were selling well, online consumption grew rapidly, and service consumption demand continued to be released. Offline passenger traffic has gradually picked up, and new consumption scenes such as characteristic commercial blocks and brand experience stores have emerged, which has driven the continuous improvement of physical store operations.
In the latest research report, soochow securities believes that the textile and apparel industry will make brilliant achievements in 2023 thanks to the post-epidemic restoration. In 2024, the growth rate of overall clothing consumption slowed down compared with that in 2023 due to the improvement of the base and the overall consumption environment, but the structural repair continued, and new trends brought new opportunities.
Tongyu Communication: The controlling shareholder intends to transfer 5% of the company’s shares by agreement.
() On the evening of January 29th, it was announced that Wu Zhonglin, the controlling shareholder and actual controller of the company, planned to transfer 20,102,800 unrestricted shares of the company to Guangzhou Pyramid Investment Management Co., Ltd.-Pyramid Harmony No.1 Private Equity Investment Fund by agreement transfer, accounting for 5% of the company’s total share capital. The transfer price of this agreement is 12.969 yuan/share, and the total price of share transfer is 261 million yuan. This share transfer did not lead to the change of the company’s controlling stake.
Tianbang Food: Some fundraising projects plan to change the implementation subject.
On the evening of January 29th, () announced that the company held the 24th meeting of the 8th Board of Directors and 22nd meeting of the 8th Board of Supervisors on January 29th, 2024, and deliberated and passed the Proposal on Changing the Implementation Subjects of Some Fundraising Projects. In order to further optimize the company’s management and business structure and improve the efficiency of the company’s operation and management, it was agreed that the company would approve the pig breeding project of Huoqiu Huisheng Breeding Co., Ltd. and Kenli District of Dongying City.
Jinyang Co., Ltd.: Signed an investment contract with Xiaogan Airport Economic Zone Management Committee for lithium battery precision structural parts project.
On the evening of January 29th, () announced that on January 29th, 2024, the company signed the Investment Contract of Jinyang Lithium Battery Precision Structural Parts Project with Xiaogan Airport Economic Zone Management Committee in Wuxi. The total planned investment of the project is about 800 million yuan. Among them, working capital investment is 300 million yuan, and fixed assets investment (including investment in buildings, structures and their ancillary facilities and equipment) is 500 million yuan. The project is mainly engaged in the research and development, production and sales of precision structural parts of lithium batteries. The main products are precision structural parts of square batteries and precision structural parts of cylindrical batteries.
Ligao Food plans to spend 50 million yuan to 100 million yuan to buy back shares.
Ligao Food announced that the company intends to use its own funds to repurchase RMB ordinary shares (A shares) of the company by centralized bidding transactions for the implementation of equity incentives or employee stock ownership plans. The total amount of funds to be used for repurchase this time is not less than 50 million yuan, not more than 100 million yuan, and the repurchase price is not more than 66.60 yuan/share.
Minde Electronics plans to spend 15 million to 30 million yuan to buy back shares.
Minde Electronics announced that the company intends to use its own funds to buy back some of the issued RMB ordinary shares (A shares), all of which will be cancelled and the registered capital will be reduced. The total amount of funds repurchased this time is not less than 15 million yuan and not more than 30 million yuan, and the price of repurchased shares is not more than 34.11 yuan/share.
Weigang Technology: It is planned to buy back shares at a price of 15 million to 30 million yuan.
() Announcement, it is planned to buy back shares at a price of 15 million yuan to 30 million yuan, and the repurchase price shall not exceed RMB 25 yuan per share.
In 2023, Ganneng’s on-grid electricity consumption was 15.949 billion kWh, a year-on-year increase of 69.20%.
() It was announced that in 2023, the power plants affiliated to the company realized 15.949 billion kWh of on-grid electricity, an increase of 69.20% over the same period of last year, of which, the market-oriented trading electricity was 15.592 billion kWh, accounting for 97.76% of the on-grid electricity.
Renzhi Co., Ltd.: It is expected that the operating performance loss will be reduced in 2023.
() According to the announcement, it is expected that in 2023, the demand of downstream customers of the company’s main business will recover, the business scale will increase, the profitability will improve to some extent, and the loss of operating performance will be reduced. The specific financial data shall be subject to the 2023 Annual Report disclosed by the company.
Lvkang Biochemical: It is estimated that the company will accrue asset impairment of about 85 million yuan.
() According to the announcement, during the reporting period, the company’s comprehensive gross profit margin fell sharply, mainly due to the downturn in the aquaculture industry, the continuous decline in the price index of veterinary drug raw materials, and the depreciation of fixed assets. In addition, the company expects to accrue about 85 million yuan in asset impairment, including about 24 million yuan in asset impairment provision for animal insurance business, about 12.6 million yuan in goodwill impairment provision, and about 48.4 million yuan in inventory depreciation loss. At the same time, the newly-built projects of Lvkang (Haining) Film Material Co., Ltd., a wholly-owned subsidiary invested by the company, and Lvkang Yushan are still in the construction stage, which has not yet produced economic effects, and at the same time, the corresponding management expenses have been increased. In addition, the company’s transformation into photovoltaic film industry has a large demand for construction funds and operating funds, and bank loans, financial leasing and supply chain funds have increased, resulting in an increase in financial expenses.
Fenglong shares: the company’s shares will be suspended from the market opening on January 30.
() Announcement, the controlling shareholder and actual controller of the company are planning the transfer of control rights, which is under negotiation, and there are still significant uncertainties. The company’s shares and convertible corporate bonds (Fenglong convertible bonds) will be suspended from the market opening on Tuesday, January 30, 2024, and the suspension time is expected to be no more than 2 trading days. During the suspension period, the company’s convertible corporate bonds are suspended from conversion.
Weike Technology: It is planned to buy back the company’s shares at a price of 50 million to 100 million yuan.
() Announcement, it is planned to buy back the company’s shares at a price of RMB 50 million to RMB 100 million, and the repurchase price shall not exceed 45 yuan/share.
Fenglong shares: the controlling shareholder and actual controller are planning the transfer of control rights, and the stock is suspended.
Fenglong announced on the evening of January 29 that the company received the notice from Shaoxing Chengfeng Industrial Co., Ltd., the controlling shareholder of the company, and Dong Jiangang, the actual controller, that the controlling shareholder and actual controller of the company were planning the transfer of control rights, and the matter was under negotiation, and there were still significant uncertainties. The company’s shares and convertible corporate bonds will be suspended from the opening of the market on Tuesday, January 30, and the suspension time is expected to be no more than 2 trading days.
Weike Technology: It is planned to buy back shares at a price of 50 million yuan to 100 million yuan.
Weike Technology announced on the evening of January 29th that the company plans to buy back shares at a price of 50 million yuan to 100 million yuan, which is intended to be used for equity incentive or employee stock ownership plan, and the price of repurchased shares shall not exceed 45 yuan/share.
Kefu Medical: repurchased 304,100 shares for the first time.
On the evening of January 29th, () announced that, on January 29th, 2024, the company repurchased 304,100 shares of the company for the first time by means of centralized auction trading through the special securities account, accounting for 0.15% of the company’s current total share capital, with the highest transaction price of 32.87 yuan/share and the lowest transaction price of 31.81 yuan/share, with the total transaction amount of 9,848,216.75 yuan (excluding transaction costs)
(): It is estimated that the annual operating income will return to the growth track in 2023, the profitability will be significantly restored, and the loss of Beijing production line will be narrowed.
Saimicroelectronics announced that it is expected to complete the acquisition of the overseas semiconductor industrial park where the production line is located in the first half of 2023, and the operating income of the Swedish production line will return to the growth track, and its profitability will be significantly restored. At the same time, Beijing MEMS production line (FAB3) achieved a substantial increase in operating income and narrowed losses. In addition, in recent years, the company has increased the strategic procurement of several batches of semiconductor equipment overseas, contributing a certain amount of operating income and some profits to the Group. However, during the reporting period, the company’s shareholding subsidiaries incurred losses as a whole.
Planning the change of control rights, Fenglong shares will be suspended from January 30.
On the evening of January 29th, Fenglong announced that the company received the notice from Shaoxing Chengfeng Industrial Co., Ltd., the controlling shareholder, and Dong Jiangang, the actual controller, that the controlling shareholder and actual controller of the company were planning the transfer of control rights, and the company’s shares and convertible corporate bonds were suspended from January 30th, and the suspension time is expected to be no more than 2 trading days.
Fenglong shares said that during the suspension period, the company will fulfill its information disclosure obligations in strict accordance with the provisions and requirements of relevant laws and regulations according to the progress of related matters. After the above matters are confirmed, the company will issue relevant announcements in time and apply for the resumption of trading of the company’s shares.
Weigang Technology: It is planned to buy back shares for 15 million yuan to 30 million yuan.
Weigang Technology announced on the evening of January 29th that the company plans to buy back shares at a price of 15 million yuan to 30 million yuan for the company’s employee stock ownership plan or equity incentive plan, and the repurchase price shall not exceed 25 yuan per share.
Zotye Auto: Announce the announcement of the 2023 annual performance forecast.
() According to the announcement, the company has not disclosed the specific operating income and net profit data for 2023, and the announcement reminds investors to pay attention to investment risks. The specific financial data will be subject to the 2023 annual report disclosed by the company.
Anche Zhidian: Obtained 2 patent certificates.
On the evening of January 29th, () announced that the company had recently obtained two patent certificates issued by China National Intellectual Property Administration. The patent names are respectively a sliding structure mechanical life testing device for three-phase common tank GIL, and a cable joint temperature measuring explosion-proof fire extinguishing device which is convenient for maintenance.
Kangtai medicine: the products of wholly-owned subsidiaries have obtained the registration certificate of medical devices.
On the evening of January 29th, () announced that Changsha Kangtai Yixin Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, recently received the People’s Republic of China (PRC) Medical Device Registration Certificate (in vitro diagnostic reagent) issued by Hunan Drug Administration, and the product name was blood lipid test card (dry chemistry method).
Sui Hengyun A plans to establish a company with China Petrochemical to build a polypropylene plant project.
Sui Hengyun A announced that the company intends to participate in the establishment of Guangzhou Mingzhu High-end New Materials Co., Ltd. (tentative name, subject to the final approval of the registration authority), and invest in the construction of a 350,000-ton/year polypropylene plant joint venture project of Guangzhou Petrochemical’s safe, green and high-quality development technology transformation project. The total investment of this project is 1,266.49 million yuan, and the project capital accounts for 30% of the total investment, that is, the registered capital of Guangzhou Mingzhu High-end New Materials Co., Ltd. is 380 million yuan.
Among them, the company contributed 38 million yuan in cash, holding 10% of its equity; Guangzhou Industrial Investment Holding Group Co., Ltd. ("Guangzhou Industrial Control") invested RMB 38 million in cash and held 10% of its equity; China Petrochemical Co., Ltd. ("China Petrochemical") invested RMB 304 million in cash and held 80% of its shares. The required project funds other than capital are financed by bank loans.
According to the announcement, China Petrochemical is currently fully participating in the construction of the national new energy market, and has broad cooperation prospects with the company in the four strategic sectors of "electricity, heat, hydrogen and storage". Through project cooperation, it will promote the company to form a long-term and stable cooperative relationship with China Petrochemical in new energy, promote the company’s leading role in comprehensive energy development in Greater Bay Area, and comprehensively enhance the company’s core competitiveness.
Kangtai Medical Subsidiary received a medical device registration certificate.
Kangtai Medical announced that Changsha Kangtai Yixin Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, recently received the Medical Device Registration Certificate (in vitro diagnostic reagent) issued by Hunan Drug Administration. The product name is: blood lipid test card (dry chemistry method).
Yiheda was increased by 342,700 shares by controlling shareholder Jin Liguo.
() Announcement: Jin Liguo, the controlling shareholder of the company, has been holding more than half of the planned time, and has accumulated 342,700 shares of the company, with an accumulated holding amount of 10,060,400 yuan (excluding transaction costs).
Langkun Environment signed cooperation framework agreement with PetroChina in South China.
Langkun environmental announcement, the company recently signed the "Cooperation Framework Agreement" with South China PetroChina International Enterprise Co., Ltd. (referred to as "South China PetroChina"). The two sides will carry out close business cooperation within a certain period of time.
According to the agreement, the two sides agreed to carry out comprehensive cooperation in the following business areas: strengthen future business cooperation on SAF (sustainable aviation fuel) products. Strengthen the follow-up business cooperation on UCO (industrial mixed oil) products. Strengthen cooperation in bio-ship fuel business. Continue to consolidate the traditional first-generation biodiesel business cooperation. Strengthen cooperation in carbon emissions trading. Joint research to promote investment cooperation of entity projects.
Osekan: Three APIs of the subsidiary were approved for listing.
On the evening of January 29th, Osekan announced that Nanjing Hairun Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, had recently received the Notice of Approval for the Listing of Chemical Raw Materials, which was issued by National Medical Products Administration. Dexlansoprazole for injection, Etroppa ethanolamine tablets and toremifene citrate tablets were approved for marketing in January 2024, respectively. The approval of the marketing of the three raw materials will enhance the competitiveness of the integration of the company’s characteristic raw materials and preparations, and enhance the company’s cost advantage and comprehensive operational efficiency.
New Cape: Received 2,517,400 yuan of VAT refund for software products.
On the evening of January 29th, () announced that on January 29th, 2024, the company received a total of 2,517,412.16 yuan of VAT refund for software products. With the approval of the Taxation Bureau of Zhengzhou High-tech Industrial Development Zone, State Taxation Administration of The People’s Republic of China, the portion of the company’s software product income whose actual tax burden exceeds 3% in November 2023 enjoys the preferential tax policy of immediate withdrawal.
Tianli Lithium Energy: 73,000 shares were repurchased on January 29th.
On the evening of January 29th, () announced that on January 29th, 2024, the company repurchased shares for the first time by centralized bidding, and the number of repurchased shares was 73,000, accounting for 0.06% of the company’s current total share capital. The highest transaction price was 26.01 yuan/share, the lowest transaction price was 25.64 yuan/share, and the total transaction amount was 1,887,500.
Affected by goodwill and asset impairment, Zhonghong Medical’s performance is pre-lost.
() It was announced on the evening of January 29th that the company expected to realize operating income of 2.1 billion yuan to 2.2 billion yuan, compared with 1.573 billion yuan in the same period of last year. It is estimated that the net profit loss in 2023 will be 103 million yuan to 154 million yuan, compared with a profit of 66.92 million yuan in the same period last year. It is estimated that the non-net profit loss will be 179 million yuan to 268 million yuan in 2023, compared with 69.82 million yuan in the same period of last year.
Regarding the reasons for the change in performance, Zhonghong Medical said that during the reporting period, the company’s foreign acquisitions continued to land and its operating income grew steadily. However, the price recovery of the company’s original nitrile and PVC protective gloves was slow, resulting in a low level of gross profit of related businesses during the reporting period. Affected by the change of market supply and demand, due to the principle of prudence, the company’s provision for impairment of fixed assets and inventories affected about RMB 18 million to RMB 35 million.
At the end of the reporting period, the evaluation agency hired by the company made a preliminary evaluation and calculation of the goodwill formed by the company’s acquisition of Hengbaokang. Combined with factors such as industry development, market changes and actual operation, it is judged that the goodwill formed by Hengbaokang shows signs of impairment. According to the Accounting Standards for Business Enterprises No.8-Impairment of Assets and other relevant accounting policies, it is estimated that the amount of impairment of goodwill will be about RMB 60 million to RMB 90 million.
Zhonghong Medical estimates that the impact of non-recurring gains and losses on net profit is about 75 million yuan to 113 million yuan, mainly due to wealth management income and government subsidies.
Zhonghong Medical announced on January 30, 2023 that the company intends to acquire 70% equity of Hengbao Health with some over-raised funds of 541 million yuan. Hengbao Health mainly sells latex gloves and condoms, among which latex gloves are mainly medical surgical gloves, supplemented by medical examination gloves, and surgical gloves take into account common products and special products such as polyisoprene, wet hand wear, double-layer and double-color.
Zhonghong Medical said at that time that the acquisition of 70% equity of Hengbao Health is an important part of the company’s layout on the new track, which can promote the overall development of the company in the big health medical industry. Through this transaction and subsequent integration, it will help the company to upgrade its products, further give play to its advantages in scale and efficiency, boost domestic and foreign sales and reduce production costs.
Zhonghong Medical also mentioned in the 2023 semi-annual report that as of the disclosure date of the report, the company has completed the acquisition of Kelun Medical Equipment and Hengbao Health, and realized the layout of products such as safe infusion devices, latex medical surgical gloves and condoms. Among them, Hengbao has obvious advantages in health innovation, and its many innovative products have a large market space and an important position in the country and even the world. The listing of these products will bring broader benefits to the company.
Unexpectedly, however, the impairment of goodwill caused by the acquisition of Hengbaokang became an important reason for the loss of net profit of Zhonghong Medical in 2023.
In the second half of 2023, Zhonghong Medical is still making foreign acquisitions.
In September 2023, Zhonghong Medical announced that according to the strategic development needs of the company, it plans to sign an equity transfer agreement to acquire 70% equity of Medrena with some over-raised funds not exceeding 58,881,200 yuan. As the consideration of this partial acquisition involves subsequent performance gambling, the actual payment consideration amount of 70% equity of the target company is subject to the completion of the final performance gambling.
Zhonghong Medical said that the acquisition of 70% equity of Medrena is to further expand the company’s innovation incubation division, speed up the development of new tracks, enrich the company’s product line, promote the company’s overall development in the medical device industry, and realize the vision of building the company into a global sustainable comprehensive medical and health products and services provider.
Fenglong shares suspended planning control rights changes.
Fenglong shares announced that the company received a notice from Shaoxing Chengfeng Industrial Co., Ltd., the controlling shareholder of the company, and Dong Jiangang, the actual controller, on January 29, 2024. The controlling shareholder and actual controller of the company are planning the transfer of control rights, which is under negotiation and there are still significant uncertainties. The company’s shares and convertible corporate bonds will be suspended from the opening of the market on January 30, 2024, and the suspension time is expected to be no more than 2 trading days.
Weike Technology plans to spend 50 million yuan to 100 million yuan to buy back shares.
Weike Technology announced that the company intends to buy back the company’s shares with its own funds, and will use the repurchased shares to implement equity incentives or employee stock ownership plans at an appropriate time in the future. The total amount of funds for this share repurchase is not less than 50 million yuan and not more than 100 million yuan, and the repurchase price is not more than 45 yuan/share.
Weigang Technology plans to spend 15 million to 30 million yuan to buy back shares.
Weigang Technology announced that the company intends to use its own funds to buy back the company’s shares by centralized bidding, which will be used for equity incentives or employee stock ownership plans. The total amount of this repurchase is not more than 30 million yuan and not less than 15 million yuan, and the repurchase price is not more than 25 yuan/share.
(): It is estimated that the profit in 2023 will be 645-730 million yuan, with a year-on-year increase of 15%-30%.
On the evening of January 29th, Iflytek announced that the annual net profit of returning to the mother in 2023 is expected to be 645-730 million yuan, a year-on-year increase of 15%-30%.
Iflytek said that during the reporting period, the company continued to invest in the "iFLYTEK Spark Cognitive Model" and maintained its leading position in the industry. At the same time, it continued to increase the investment in domestic independent research and development in core technologies and industrial support, and formed the leading achievement of "Feixing No.1" on the domestic computing base. Under the background of the above-mentioned high-intensity investment, the company still achieved positive growth in revenue and gross profit, and achieved positive net profit, non-net profit deduction and cash flow, maintaining a healthy and healthy development of its operation.
Iflytek introduced that in 2023, the company is expected to achieve operating income of more than 20 billion yuan, an increase of about 7% over the previous year, while maintaining the gross profit margin not lower than that of the previous year. As of December 31, 2023, the company’s net operating cash flow exceeded 300 million yuan.
Among them, Iflytek’s performance in the fourth quarter of 2023 has rebounded significantly, and it is estimated that its operating income will exceed 7.5 billion yuan, an increase of more than 20% over the same period of last year, and its gross profit will exceed 3.2 billion yuan.
Iflytek said that the Spark Model V3.5 will be officially released on January 30th, and this version has greatly improved its abilities in logical reasoning, language understanding, text generation, mathematical answering, code and multi-mode, further approaching the latest level of GPT-4Turbo. At the same time, the Spark Voice Model will be released for the first time, which has surpassed Whisper-large-v3 launched by OpenAI in the first batch of 37 mainstream languages, keeping the international leading level of intelligent voice technology in Iflytek. In addition, the company will also release the first iFLYTEK Spark open source model which is deeply adapted to domestic computing power.
Jinyang Co., Ltd. further expands its production capacity and plans to increase its foreign investment by 800 million yuan.
On the evening of January 29th, Jinyang Co., Ltd. announced that it had signed the Investment Contract for the Precision Structural Parts Project of Lithium Battery of Jinyang Co., Ltd. with the Management Committee of Xiaogan Airport Economic Zone. The total planned investment of the project is about 800 million yuan. Among them, working capital investment is 300 million yuan, and fixed assets investment (including investment in buildings, structures and their ancillary facilities and equipment) is 500 million yuan.
According to the announcement, the project is mainly engaged in the research and development, production and sales of precision structural parts of lithium batteries. The main products are precision structural parts of square batteries and precision structural parts of cylindrical batteries.
It is reported that as one of the leading manufacturers of battery precision structural parts and materials in China, Jinyang Co., Ltd. focuses on providing battery precision structural parts and materials with high precision, high consistency and high safety for the battery industry. The company’s main business is the research, development, production and sales of battery precision structural parts and materials. The main products are battery packaging cases, safety valves and nickel-based conductor materials, forming a complete product system from packaging cases and safety valves to nickel-based conductor materials, which enjoys a high reputation in the industry.
For this cooperation, Jinyang Co., Ltd. said that with the rapid development of new energy vehicles and energy storage markets at home and abroad, it aims to further expand the production capacity layout to meet the supporting needs of customers’ production capacity and enhance the company’s industry influence and comprehensive competitiveness.
In terms of benefit forecast, the company said that the annual output value of the project was more than 1.6 billion yuan and the annual tax revenue was more than 50 million yuan after it was officially put into production.
Jinyang Co., Ltd. said that this foreign investment is in line with the national industrial policy and the company’s long-term development strategic plan, which is conducive to the company’s improvement of production capacity layout and ability to respond quickly to customer needs, and has positive significance for the company’s future development.
Huasen Pharmaceutical rasagiline Mesylate Tablets obtained the drug registration certificate.
Huasen Pharmaceutical announced on the evening of January 29th that the company recently received the relevant Drug Registration Certificate (CertificateNo.: 2024S00109) approved and issued by National Medical Products Administration, and its declared "rasagiline Mesylate Tablets (registration classification: Class 4 chemicals; Specification: 1mg) "After examination, it meets the relevant requirements of drug registration and is approved for registration.
According to the data, rasagiline mesylate tablets are suitable for the single treatment of patients with primary Parkinson’s disease (PD) (without levodopa) and for Parkinson’s patients with terminal fluctuation as an auxiliary drug of levodopa, and are recommended by Guidelines for the Treatment of Parkinson’s Disease in China, Guidelines for the Diagnosis and Treatment of Mild Cognitive Impairment of Parkinson’s Disease in China (2020 Edition) and Guidelines for Evidence-based Medicine for the Treatment of Motor Symptoms of Parkinson’s Disease in China.
The drug is a new and selective second-generation irreversible monoamine oxidase (MAO-B) inhibitor, which can effectively inhibit MAO-B activity and block dopamine decomposition in the brain. At the same time, it can increase the extracellular level of dopamine in striatum, and the increased dopamine level and its subsequent dopaminergic activity can adjust dopaminergic motor dysfunction. In addition, compared with other anti-PD drugs, it has the advantages of neuroprotection, neuroplasty and long-term synergistic effect, and can be used as a first-line single drug for early treatment or levodopa as an auxiliary drug for the treatment of PD.
Rasagiline mesylate tablet is a Class B drug of national medical insurance, and it is a generic drug independently developed by the company. At present, the company is the fourth approved generic drug manufacturer in China, and the quality and efficacy of the drug are equivalent to the original research product. According to the data of Yaozhi. com, the overall market share of this drug will be 121 million yuan in 2022.
Huasen Pharmaceutical said that the "Drug Registration Certificate" for rasagiline Mesylate tablets will help to further enrich the company’s product line, enhance the company’s market competitiveness, and benefit more patients. At the same time, it will also help to form a market synergy with the company’s existing Duliang soft capsules, Liuwei Anshen capsules and other products in the field of mental nervous system, create a product cluster in advantageous fields, and have a positive impact on the company’s production and operation.
Pingda New Materials Actively Maintains the Stability of Renzhi’s Control.
Renzhi Co., Ltd. announced on January 30 that 18.64% of the company’s equity held by Tibet Hanyi, the former major shareholder of the company, is facing judicial auction. However, the existing controlling shareholder of the company with voting rights, Pingda New Materials, intends to defend the status of the major shareholder by participating in the judicial auction of the equity.
After Pingda New Materials held Renzhi shares, the board of directors and senior management team changed, and the company was able to take off its star and hat, and its operation continued to forge ahead. In order to increase Renzhi shares’ capital and enrich its operating funds, Pingda New Materials planned to subscribe for the company’s share issuance to a specific target in full with no more than 253 million yuan in cash, and the project has been approved by Shenzhen Stock Exchange, and all the funds raised from the share issuance will be used to support the company’s development. According to the online judicial auction platform of JD.COM, the starting price of the judicial auction of 81,387,013 shares of Hanli in Tibet totaled 259 million yuan. According to Renzhi’s announcement, Pingda New Materials paid a judicial auction deposit of 30.3 million yuan at the first time. According to the analysis of professionals, the auction of the equity of Tibet Hanli, the former major shareholder, is an inevitable opportunity for Pingda New Materials to consolidate its controlling position.
According to the announcement, on January 29th, 2024, the company received a notice from Tibet Hanli, the former major shareholder, and inquired about the online judicial auction platform in JD.COM. The shares to be auctioned this time are 81,387,013 shares held by Tibet Hanli Electronic Technology Partnership (Limited Partnership), the former major shareholder of Zhejiang Renzhi Co., Ltd. ("Tibet Hanli" for short), accounting for 18.64% of the company’s total share capital and accounting for the shares held by Tibet Hanli.
According to the announcement, at present, the auction of shares of the company held by Tibet Han Li is still in the publicity stage, and the follow-up may involve bidding, payment, court enforcement of legal procedures, equity change and transfer. If the above procedures are completed, the company will fulfill the corresponding information disclosure obligations according to the final results.
According to the announcement, Pingda New Materials Co., Ltd. (hereinafter referred to as "Pingda New Materials"), the company’s current controlling shareholder, has issued the Commitment on Safeguarding the Stability of Control Rights of Listed Companies in 2021. Before this issuance, if Tibet Hanli holds 81,387,000 shares of the company and is subject to judicial auction, Pingda New Materials will be transferred to the issuer through judicial auction, including but not limited to secondary market increase, block trade and agreement transfer. As of the disclosure date of this announcement, Pingda New Materials has paid a total deposit of RMB 30.3 million to participate in the auction according to the above commitment, and will actively participate in this judicial auction.
It is understood that Pingda New Materials, the controlling shareholder of the company, directly holds 10,000 shares of the company, and 81,387,013 shares of the company are entrusted by Tibet Hanli voting rights, so the total number of shares with voting rights of listed companies is 81,397,013, accounting for 18.64% of the total share capital of listed companies. If the shares of the company held by Tibet Hanli are successfully auctioned and won by parties other than Pingda New Materials and its concerted parties, the number and proportion of shares with voting rights of the company will change, which may lead to changes in the controlling shareholders and actual controllers of the company. The controlling shareholder, Pingda New Materials, has paid the deposit and prepared funds to actively participate in this judicial auction as promised, so as to maintain the stability of control rights. Pingda New Materials participated in the project of issuing shares to specific targets and the total investment in this judicial auction was not less than 512 million yuan. Judging from the fact that Pingda New Materials paid the deposit for the share auction at the first time, Pingda New Materials seems to be well prepared to consolidate the control of Renzhi shares and help the subsequent business development of Renzhi shares.
The announcement also explained that the auction is still in the publicity stage, and the follow-up will involve bidding, payment, equity change and transfer, and there are still some uncertainties in the auction results. At present, the daily production, operation and management of listed companies are carried out normally.
According to the analysis, through the attitude of Pingda New Materials to participate in the judicial auction of Renzhi shares, its determination to further consolidate its control position in listed companies and land in the capital market strongly should not be underestimated. (Tao Jun)
Zhang Xiaoquan plans to spend 30 million yuan to 40 million yuan to implement repurchase, and the repurchase price does not exceed 20.66 yuan/share.
Zhang Xiaoquan announced that the company intends to buy back its shares for employee stock ownership plan or equity incentive. The total amount of funds repurchased is not less than 30 million yuan (inclusive) and not more than 40 million yuan (inclusive); The repurchase price shall not exceed 20.66 yuan/share (inclusive). The implementation period of share repurchase shall not exceed 12 months from the date when the board of directors deliberated and approved the share repurchase plan.
Jingfeng Medicine: It is estimated that the net profit will be lost in 2023, and the net assets at the end of the period will be negative.
() According to the announcement, it is expected that in 2023, due to factors such as the sharp decline in sales of important products, the stagnation of subsidiaries and the full long-term asset impairment test, the net profit will be lost. The company also stated that it expects the net assets at the end of 2023 to be negative, and the specific data has not been audited by accounting firms. If the audited net assets at the end of the period are negative, the company’s shares may be warned of delisting risk after the disclosure of the 2023 annual report. In addition, the company also suggested that there is still uncertainty whether the company will enter the reorganization procedure. If the court formally accepts the applicant’s application for reorganization of the company and the reorganization is successfully implemented, it will help improve the company’s asset-liability structure and push the company back to the track of sustainable development. However, there is still the risk of bankruptcy liquidation due to the failure of reorganization in the later stage.
Tianqin Equipment: It is planned to buy back the company’s shares at a price of 12 million to 24 million yuan.
() Announcement, it is planned to buy back the company’s shares at a price of 12 million yuan to 24 million yuan, and the repurchase price shall not exceed 16.5 yuan per share.
Tianqin Equipment: It is planned to buy back the company’s shares at a price of 12 million to 24 million yuan.
Tianqin Equipment announced on the evening of January 29th that it plans to buy back the company’s shares at a price of 12-24 million yuan, with the repurchase price not exceeding 16.5 yuan/share. The repurchased shares will be used to safeguard the company’s value and shareholders’ rights and interests.
() It is planned to spend 30 million yuan to 60 million yuan to implement repurchase, and the repurchase price shall not exceed 15.06 yuan/share.
Huaxin Environmental Protection announced that the company intends to use its own funds to buy back the company’s shares in a centralized bidding transaction for the implementation of equity incentives or employee stock ownership plans. The total amount of repurchase funds is not less than 30 million yuan (inclusive), not more than 60 million yuan (inclusive), and the price of repurchased shares is not more than 15.06 yuan/share (inclusive). The time limit for repurchasing shares is within 12 months from the date when the company’s board of directors deliberated and approved the plan for repurchasing shares.
Ligao Food plans to spend 50 million yuan to 100 million yuan to implement repurchase, and the repurchase price does not exceed 66.6 yuan/share.
Ligao Food announced that the company intends to use its own funds to repurchase the company’s A shares in a centralized bidding transaction for the implementation of equity incentives or employee stock ownership plans. The total amount of funds repurchased is not less than 50 million yuan (inclusive) and not more than 100 million yuan (inclusive), and the repurchase price is not more than 66.6 yuan/share (inclusive). The implementation period of the repurchase is within 12 months from the date when the company’s board of directors deliberated and approved this share repurchase plan.
Tianqin Equipment plans to spend 12 million to 24 million yuan to buy back shares.
Tianqin Equipment announced that the company intends to use its own funds to buy back some public shares of the company in a centralized bidding transaction, which is necessary to safeguard the company’s value and shareholders’ rights and interests. The total amount of funds repurchased this time is not more than 24 million yuan, not less than 12 million yuan, and the price of repurchased shares is not more than 16.50 yuan/share.
Zhengyuan Wisdom: It is planned to buy back shares for 40 million yuan to 80 million yuan.
() It was announced on the evening of January 29th that the company plans to buy back some shares of the company at a price of 40 million yuan to 80 million yuan, and sell them within the specified time limit, with the repurchase price not exceeding 20 yuan/share.
Ba ‘an Water received the enforcement notice.
() It was announced on the evening of January 29th that recently, Shanghai Maiye, the executor of the application, applied to the Qingpu District People’s Court of Shanghai for execution, and the executed persons, the subsidiary of Baan Water, Ganzhou Nankang District Baan Water Purification Co., Ltd. and Anfu County Baan Water Purification Co., Ltd., received the Notice of Execution from the Qingpu District People’s Court of Shanghai. According to the disclosure, the person subjected to execution should pay 310 million yuan and interest to Shanghai Maiye, and the execution fee is 377,600 yuan. The company said that the impact of this case on the company’s current profit or future profit is subject to the company’s annual audit report.
According to the announcement, Ba ‘an Water previously signed a Debt Restructuring Contract with Galaxy Assets for "H7 Ba ‘an Debt", and later Galaxy Assets signed a Debt Transfer Agreement with Shanghai Maiye, and the creditor has changed from Galaxy Assets to Shanghai Maiye. Regarding the performance of the above debts, Shanghai Maiye applied to Beijing Chang ‘an Notary Office for an execution certificate on March 14, 2023, and Beijing Chang ‘an Notary Office issued the (2023) J.C.Z.Zi No.89 Execution Certificate, which Shanghai Maiye can apply to the people’s court with jurisdiction for execution. On April 21st, 2023, Shanghai Maiye agreed to extend the debt term under the above contract to October 31st, 2023. Up to now, the company has failed to pay the principal and interest on schedule due to the tight financial situation.
Tianyang Technology: The estimated net profit in 2023 is 110-135 million yuan.
() On January 29th, the announcement of pre-increase in performance in 2023 was released. It is estimated that the net profit will be 110-135 million yuan, up by 81.10%-122.25% year-on-year, and the non-net profit will be 57-82 million yuan, up by 246.34%-398.25% year-on-year.
According to the company, in 2023, Tianyang Technology will resolutely implement the strategy of excellent operation and development, focus on the high-quality development of core business, focus on strategic customers to improve the efficiency and quality of project delivery, and continuously improve customer satisfaction. With advanced product and solution capabilities and professional digital technology capabilities, it will help customers develop their business rapidly and create value for customers.
At the same time, in 2023, the company will continue to build a team of highly influential experts in the professional field, speed up the training of management cadres, optimize the structure of project management talents and professional and technical talents, and provide a strong guarantee for the high-quality development of the company’s business.
It is understood that in 2023, Tianyang Technology will continue to strengthen the management of accounts receivable, further improve the payment assessment mechanism, promote the on-line acceptance of the project on schedule and timely recover the project funds, and intensify the cleaning up of long-aged accounts receivable. In 2023, the company’s operating cash flow improved significantly and turned positive, and it is expected that the provision for credit impairment will decrease year-on-year. The company’s overall operating performance has risen steadily and developed with high quality.
According to the announcement, during the reporting period, the company estimated that the impact of non-recurring gains and losses on the net profit attributable to shareholders of listed companies was about 53 million yuan, mainly due to government subsidies and wealth management income, which had a positive impact on the profit growth during the reporting period.
Kallet: It is estimated that the operating income and net profit attributable to shareholders of listed companies will increase year-on-year in 2023.
() According to the announcement, it is estimated that in 2023, the company’s operating income and net profit attributable to shareholders of listed companies will increase year-on-year. The main reason is that the company closely focuses on the established development strategy and actively promotes the implementation of the equity incentive plan. In the domestic market, the application scenarios of LED display control industry are increasing, the company’s core products increase with the increase of downstream shipments, and the growth rate of operating income is obvious. In overseas markets, the company increased the construction of marketing outlets in North America and Europe, improved pre-sales and after-sales services, and expanded the coverage of high-end products in overseas markets. In 2023, the company’s non-recurring profit and loss is estimated to be about 20 million to 30 million, mainly due to wealth management income and government subsidies.
(): It is estimated that the operating income will increase year-on-year in 2023, and the net profit will be affected by 21 million to 23 million.
Su Wen Power announced that it is expected that during the reporting period in 2023, the company’s revenue will increase year-on-year and its overseas business will make a breakthrough. As the company has increased the investment in power electronic equipment and optical storage and charging business, it has maintained a high R&D expenditure, and strengthened the introduction of talents for this purpose, resulting in a sustained net increase in the number of employees and an increase in the overall labor cost. At the same time, the company strengthened the management of accounts receivable and increased the dunning of accounts receivable. In 2023, the net operating cash flow increased year-on-year. However, due to the insufficient payment of historical accounts receivable, the migration rate of accounts receivable increased, and the provision for credit impairment increased year-on-year. During the reporting period, the impairment of some assets of the company increased significantly compared with the same period of last year. The company has communicated with the accounting firm on this matter, and has hired a professional appraisal agency to make a preliminary assessment of these assets, and the impairment of these assets has increased compared with the same period of last year. The company’s non-operating profit and loss are mainly government subsidies and investment income of wealth management products, and the estimated impact on net profit is 21 million to 23 million. The above data is the result of preliminary calculation, and the specific situation is subject to the final audit evaluation data.
Weike Technology plans to spend 50 million yuan to 100 million yuan to implement repurchase, and the repurchase price does not exceed 45 yuan/share.
Weike Technology announced that the company intends to repurchase shares for equity incentives or employee stock ownership plans; The total amount of funds for repurchasing shares is not less than 50 million yuan (inclusive) and not more than 100 million yuan (inclusive); The price range shall not exceed 45 yuan/share (inclusive). The implementation period of the share repurchase is within 12 months from the date when the company’s board of directors deliberated and approved the repurchase plan.
Langjin Technology: The revenue of new business segments has increased substantially, and it is expected to turn losses into profits in 2023.
On the evening of January 29th, () announced that the company expected the net profit attributable to shareholders of listed companies to be 10 million yuan to 15 million yuan in 2023, turning losses into profits year-on-year.
Regarding the growth of performance, Langjin Technology said that on the basis of the steady development of rail transit business, the company actively explored new business areas, and increased product research and development and market layout in the fields of heat pump drying, new energy vehicles, energy storage and data centers. The product income of new business segments increased substantially, realizing the sustained growth of the company’s operating income. At the same time, the company optimized its management mechanism, improved its internal operating efficiency, continued to optimize product design, strengthened the optimization of supply chain system, and reduced the cost and control fees, which greatly increased the comprehensive gross profit margin of the company’s product sales.
According to the data, Langjin Technology is a leading enterprise in the field of rail transit air conditioning in China. In 2023, the company completed the delivery of air-conditioning orders for vehicles on several rail transit lines at home and abroad, including Chengdu, Fuzhou, Zhengzhou, Wuhan, Qingdao, Wenzhou, Xi ‘an, Tianjin, Chongqing, Changchun and Romania, which helped the company’s performance to grow steadily.
Expand the production capacity layout Jinyang Co., Ltd. plans to build a new lithium battery precision structural component project of about 800 million yuan.
Jinyang Co., Ltd. announced that on January 29, 2024, the company signed the Investment Contract of Jinyang Co., Ltd. Lithium Battery Precision Structural Parts Project with the Management Committee of Xiaogan Airport Economic Zone in Wuxi City. The total planned investment of the project is about 800 million yuan. The project is mainly engaged in the research and development, production and sales of precision structural parts of lithium batteries. The main products are precision structural parts of square batteries and precision structural parts of cylindrical batteries.
The intended plot of the project is located in the high-tech industrial park of Xiaogan Linkong Economic Zone, and the fourth part of the project is: east of Lingyun Avenue, south of Fengqi Road, west of Nongyang Road and north of Anyang Road. The planned total land area is about 113 mu.
According to the announcement, this foreign investment is mainly to further expand the production capacity layout, meet the supporting needs of customers’ production capacity, and enhance the company’s industry influence and comprehensive competitiveness.
The subsidiary of Gaole Co., Ltd. signed a cooperation agreement on research and development of related technologies for nano-solid sodium ion batteries
Gaole shares announced that Gaole New Energy Technology (Zhejiang) Co., Ltd. (hereinafter referred to as "Gaole New Energy" or "Party A"), a wholly-owned subsidiary of the company, and Chongqing Nikolai Science and Technology Industry Research Institute Co., Ltd. (hereinafter referred to as "Nikolai Research Institute" or "Party B") signed the Technical Research and Development Cooperation Agreement for the Development and Research Project of Nanometer Solid Sodium Ion Battery on January 28, 2024, and Party A entrusted Party B to research and develop "Nanometer Solid Sodium Ion" The two sides reached this cooperation agreement through equal consultation and on the basis of truly and fully expressing their respective wishes.
According to the announcement, the cooperation between the company and Nikolai Research Institute is conducive to achieving mutual benefit and promoting the development and implementation of new business of the company’s wholly-owned subsidiaries, which is conducive to enhancing the company’s overall competitiveness and profitability, enhancing the company’s future operating performance, and benefiting the company’s sustained, healthy and steady development.
Guangdong Electric Power A: In A：2023, the power generation was 120.553 billion kWh, up 5.7% year-on-year.
Guangdong Electric Power A announced that in 2023, the company completed a total of 120.553 billion kWh of power generation with consolidated statements, an increase of 5.70% year-on-year; Among them, coal power completed 95.639 billion kWh, up 2.15% year-on-year, gas power completed 18.511 billion kWh, up 23.09% year-on-year, wind power completed 4.903 billion kWh, up 14.05% year-on-year, hydropower completed 411 million kWh, up 9.31% year-on-year, biomass completed 708 million kWh, down 0.14% year-on-year, and photovoltaic completed 3.82.
The company has completed a total of 113.998 billion kWh of online electricity in the consolidated statements, an increase of 5.88% year-on-year; Among them, coal power completed 89.735 billion kWh, up 2.20% year-on-year, gas power completed 18.144 billion kWh, up 23.02% year-on-year, wind power completed 4.718 billion kWh, up 14.63% year-on-year, hydropower completed 403 million kWh, up 8.92% year-on-year, biomass completed 622 million kWh, down 0.96% year-on-year, and photovoltaic completed 3.76.
Chen Xi, the head of WANDA CINEMAS Welcome New Beauty Producer, is the chairman and president.
Recently, () announced the election of Ms. Chen Xi (stage name: Chen Zhixi) as the new chairman and president of the company, which attracted wide attention from both inside and outside the industry. According to the announcement, after the election, the sixth board of directors of WANDA CINEMAS will be composed of six directors, including four non-independent directors and two independent directors. After deliberation, the board of directors unanimously agreed to elect Chen Xi as the chairman of the sixth board of directors of the company, with a term of office from the date of deliberation and approval by the board of directors to the expiration of the term of office of the sixth board of directors. At the same time, the legal representative of the company will also be changed to Chen Xi.
Chen Xi, whose stage name is Chen Zhixi, is a well-known beauty producer with rich experience in film production and producer. She has worked as a producer and producer of many popular movies, including Passion, Keep You Safe, Hi, Mom, The Reunions, Animal World, detective chinatown, Sorry for Thailand and so on. These works not only achieved excellent results at the box office, but also won the recognition of the audience in word of mouth and quality. According to statistics, the cumulative box office of films produced by Chen Zhixi has exceeded 10 billion, among which the box office of Hi, Mom, a film released in the Spring Festival in 2021, is as high as 5.413 billion, which has become another peak of her career.
Chen Zhixi’s outstanding achievements and profound strength in the film industry make her known as one of the most powerful producers in the industry. Her joining will undoubtedly inject new vitality and creativity into WANDA CINEMAS. As the new chairman and president, Chen Zhixi will lead WANDA CINEMAS to continue to deepen the film market, expand business areas, enhance brand influence and bring more high-quality and diverse film works to the audience. The election of Chen Zhixi as chairman and president in WANDA CINEMAS is not only an affirmation of her personal ability and achievements, but also an expectation and trust for her future development.
Weigang Technology plans to buy back 15 million yuan to 30 million yuan, and the repurchase price does not exceed 25 yuan/share.
Weigang Technology announced that the company intends to use its own funds to buy back the company’s shares by centralized bidding, and the repurchased company’s shares will be used for equity incentives or employee stock ownership plans. The total amount of this repurchase is not more than RMB 30 million (inclusive) and not less than RMB 15 million (inclusive), and the repurchase price is not more than RMB 25 yuan/share (inclusive). The repurchase period is 12 months from the date when the company’s board of directors deliberated and approved this repurchase plan.
The controlling shareholder and actual controller of Fenglong Co., Ltd. are planning the transfer of control, and the suspension will be suspended from January 30.
Fenglong Co., Ltd. issued an announcement. On January 29, 2024, the company received a notice from Shaoxing Chengfeng Industrial Co., Ltd., the controlling shareholder of the company, and Dong Jiangang, the actual controller. The controlling shareholder and actual controller of the company are planning the transfer of control rights. The matter is under negotiation and there are still major uncertainties.
Upon the company’s application to Shenzhen Stock Exchange, the company’s shares and convertible corporate bonds (bond code: 128143, bond abbreviation: Fenglong convertible bonds) will be suspended from the market opening on Tuesday, January 30, 2024, and the suspension time is expected to be no more than 2 trading days. During the suspension period, the company’s convertible corporate bonds are suspended from conversion.
Long Xing Chemical: "Long Xing Convertible Bonds" will start subscription on February 1st.
() Announcement: The convertible bonds issued by the company this time are referred to as "Long Xing Convertible Bonds" for short, with the bond code of "127105", and the total issued amount is RMB 754,753,900.
The priority placing date of the original shareholders of this convertible bond issue is the same as the online subscription date on February 1, 2024 (T day), and the online subscription time is 9:15-11:30 and 13:00-15:00 on T day.
Guotong shares: it is planned to publicly list and transfer 100% equity of Hebei Guoyuan and related creditor’s rights.
() It was announced in the morning of January 30th that it was planned to transfer 100% equity and related creditor’s rights of Hebei Guoyuan Water Co., Ltd. (hereinafter referred to as "Hebei Guoyuan") held by the company through the Beijing Equity Exchange, and the transfer price for the first listing was higher than the assessed amount. The transaction is to integrate the company’s high-quality resources, optimize resource allocation, improve asset structure, reduce management and investment risks, and enhance the company’s sustainable profitability.
Guotong intends to transfer 100% equity and related creditor’s rights of its subsidiary Hebei Guoyuan by listing.
Guotong shares announced that the company intends to publicly list and transfer 100% equity and related creditor’s rights of Hebei Guoyuan Water Co., Ltd. (hereinafter referred to as "Hebei Guoyuan") held by the company through the Beijing Equity Exchange, and the transfer price for the first listing is higher than the assessed amount. This asset appraisal report selects the appraisal result of income method as the appraisal conclusion. The specific appraisal conclusions are as follows: The total equity value of shareholders of Hebei Guoyuan Water Co., Ltd. is 50,753,200 yuan, which is 11,829,600 yuan higher than the book net assets of 38,923,400 yuan, with an appreciation rate of 30.39%.
In order to recover the creditor’s rights in Hebei Guoyuan at the same time, the company intends to bundle and transfer the related creditor’s rights of the company and its affiliated company Tianjin Hehai Pipe Industry Co., Ltd. in Hebei Guoyuan totaling 7,172,400 yuan (data as of the date of this meeting), so as to reduce the risk of later recovery of the company’s creditor’s rights.
According to the announcement, in order to integrate the company’s high-quality resources, optimize resource allocation, improve asset structure, reduce management and investment risks, and enhance the company’s sustainable profitability, it is in line with the company’s strategic development plan and long-term interests. As the final transaction price of this transaction has not yet been determined, the financial impact involved in this matter needs to be determined according to the results of public listing. After the completion of this equity transfer, Hebei Guoyuan will no longer be included in the scope of the company’s consolidated statements.
Zhengyuan Wisdom plans to spend 40 million yuan to 80 million yuan to buy back shares.
Zhengyuan Wisdom announced that the company plans to spend 40 million yuan to 80 million yuan to buy back shares, and the repurchase price shall not exceed 20 yuan/share. The repurchased shares are based on safeguarding the company’s value and shareholders’ rights and interests, and will be sold within the prescribed time limit in accordance with the relevant repurchase rules and regulatory guidelines.
